



Clinical trial results:

A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2016-000603-91 |
| Trial protocol | NL DE IT |
| Global end of trial date | 12 October 2021 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 (current) |
| This version publication date | 28 October 2022 |
| First version publication date | 28 October 2022 |

Trial information

Trial identification

| | |
|-----------------------|-----------|
| Sponsor protocol code | CA013-004 |
|-----------------------|-----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02754141 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|-------------------------------------------------------------------------------------------------|
| Sponsor organisation name | Bristol-Myers Squibb |
| Sponsor organisation address | Chaussée de la Hulpe 185, Brussels, Belgium, 1170 |
| Public contact | EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com |
| Scientific contact | Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com |

Notes:

Paediatric regulatory details

| | |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|------------------------------------------------------|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 29 June 2021 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|-----------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 12 October 2021 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to assess the safety and tolerability of BMS-986179 administered alone and in combination with nivolumab.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

| | |
|-----------------------------------------------------------|--------------|
| Actual start date of recruitment | 21 June 2016 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Canada: 40 |
| Country: Number of subjects enrolled | France: 75 |
| Country: Number of subjects enrolled | Germany: 5 |
| Country: Number of subjects enrolled | Italy: 18 |
| Country: Number of subjects enrolled | Australia: 8 |
| Country: Number of subjects enrolled | Netherlands: 18 |
| Country: Number of subjects enrolled | United States: 71 |
| Worldwide total number of subjects | 235 |
| EEA total number of subjects | 116 |

Notes:

Subjects enrolled per age group

| | |
|-------------------------------------------|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |

| | |
|---------------------------|-----|
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 140 |
| From 65 to 84 years | 94 |
| 85 years and over | 1 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

235 participants treated

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|-----------|
| Arm title | P1A 150mg |
|------------------|-----------|

Arm description:

BMS-986179 150mg monotherapy leading into BMS-986179 150mg + Nivo 240 combo therapy

| | |
|----------------------------------------|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

35mg/mL

| | |
|----------------------------------------|------------------|
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

10mg/mL

| | |
|------------------|-----------|
| Arm title | P1A 300mg |
|------------------|-----------|

Arm description:

BMS-986179 300mg monotherapy leading into BMS-986179 300mg + Nivo 240mg combo therapy

| | |
|----------------------------------------|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

10mg/mL

| | |
|----------------------------------------|------------------|
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

35mg/mL

| | |
|------------------|-----------|
| Arm title | P1A 600mg |
|------------------|-----------|

Arm description:

BMS-986179 600mg monotherapy leading into BMS-986179 600mg + Nivo 240mg combo therapy

| | |
|----------------------------------------|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

10mg/mL

| | |
|----------------------------------------|------------------|
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

35mg/mL

| | |
|------------------|------------|
| Arm title | P1A 1200mg |
|------------------|------------|

Arm description:

BMS-986179 1200mg monotherapy leading into BMS-986179 1200mg + Nivo 240mg combo therapy

| | |
|----------------------------------------|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

35mg/mL

| | |
|----------------------------------------|------------------|
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

10mg/mL

| | |
|------------------|------------|
| Arm title | P1A 1600mg |
|------------------|------------|

Arm description:

BMS-986179 1600mg monotherapy leading into BMS-986179 1600mg + Nivo 240mg combo therapy

| | |
|----------------------------------------|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

| | |
|----------------------------------------|--------------------------------------------------|
| Dosage and administration details: | |
| 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 10mg/mL | |
| Arm title | P1B Combo Therapy 150mg |
| Arm description: | |
| BMS-986179 150mg + Nivo 360mg | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 10mg/mL | |
| Arm title | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg |
| Arm description: | |
| BMS-986179 1200mg + Nivo 360mg | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 10mg/mL | |
| Arm title | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
| Arm description: | |
| BMS-986179 1200mg + Nivo 480mg | |
| Arm type | Experimental |

| | |
|----------------------------------------|------------------------|
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 10mg/mL | |
| Arm title | P1B BMS986-179 1600mg |
| Arm description: | |
| BMS-986179 1600mg SC | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |
| Arm title | P2 Combo Pancreatic |
| Arm description: | |
| BMS-986179 1200mg Q2W + Nivo 240mg Q2W | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 10mg/mL | |
| Arm title | P2 Combo Therapy NSCLC |
| Arm description: | |
| BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Arm type | Experimental |

| | |
|----------------------------------------|--------------------|
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 10mg/mL | |
| Arm title | P2 Combo Melanoma |
| Arm description: | |
| BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 10mg/mL | |
| Arm title | P2 Combo SCCHN |
| Arm description: | |
| BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 10mg/mL | |
| Arm title | P2 RCC Monotherapy |

| | |
|-------------------------------------------------------------------------|----------------------|
| Arm description: BMS-986179 600mg Q2W monotherapy | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: 35mg/mL | |
| Arm title | P2 RCC Combo Therapy |
| Arm description: BMS-986179 600mg Q2W + Nivo 480mg Q4W combo therapy | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: 10mg/mL | |
| Arm title | P2 Combo Prostate |
| Arm description: BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: 10mg/mL | |
| Arm title | P2 Combo Unassigned |
| Arm description: BMS-986179 1200mg Q2W + Nivo 240mg Q2W | |
| Arm type | Experimental |

| | |
|----------------------------------------|---------------------------|
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |
| Investigational medicinal product name | nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 10mg/mL | |
| Arm title | P2 Monotherapy Unassigned |
| Arm description: | |
| BMS-986179 600mg Q2W | |
| Arm type | Experimental |
| Investigational medicinal product name | BMS986179 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| 35mg/mL | |

| Number of subjects in period 1 | P1A 150mg | P1A 300mg | P1A 600mg |
|---------------------------------------|------------------|------------------|------------------|
| Started | 14 | 12 | 12 |
| Continuing to Combo Therapy | 12 | 11 | 12 |
| Crossing over to RCC combo therapy | 0 ^[1] | 0 ^[2] | 0 ^[3] |
| Completed | 1 | 2 | 4 |
| Not completed | 13 | 10 | 8 |
| Disease progression | 11 | 7 | 8 |
| Study drug toxicity | 1 | 1 | - |
| Request to discontinue | - | - | - |
| Maximum clinical benefit | - | - | - |
| AE unrelated to study drug | 1 | 1 | - |
| No longer meets study criteria | - | - | - |
| Other reasons | - | - | - |
| Withdrew consent | - | - | - |
| Completed treatment as per protocol | - | 1 | - |
| Not completing monotherapy | - | - | - |

| Number of subjects in period 1 | P1A 1200mg | P1A 1600mg | P1B Combo Therapy 150mg |
|-------------------------------------|------------------|------------------|-------------------------|
| Started | 9 | 12 | 9 |
| Continuing to Combo Therapy | 7 | 10 | 0 |
| Crossing over to RCC combo therapy | 0 ^[4] | 0 ^[5] | 0 |
| Completed | 1 | 2 | 0 |
| Not completed | 8 | 10 | 9 |
| Disease progression | 5 | 7 | 7 |
| Study drug toxicity | - | - | - |
| Request to discontinue | - | - | - |
| Maximum clinical benefit | 1 | - | - |
| AE unrelated to study drug | 1 | 3 | 2 |
| No longer meets study criteria | 1 | - | - |
| Other reasons | - | - | - |
| Withdrew consent | - | - | - |
| Completed treatment as per protocol | - | - | - |
| Not completing monotherapy | - | - | - |

| Number of subjects in period 1 | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg | P1B BMS986-179 1600mg |
|-------------------------------------|--------------------------------------------------|--------------------------------------------------|-----------------------|
| Started | 8 | 7 | 18 |
| Continuing to Combo Therapy | 0 | 0 | 0 ^[6] |
| Crossing over to RCC combo therapy | 0 | 0 | 0 ^[7] |
| Completed | 0 | 0 | 6 |
| Not completed | 8 | 7 | 12 |
| Disease progression | 7 | 6 | 11 |
| Study drug toxicity | - | - | - |
| Request to discontinue | - | - | 1 |
| Maximum clinical benefit | - | - | - |
| AE unrelated to study drug | 1 | - | - |
| No longer meets study criteria | - | - | - |
| Other reasons | - | 1 | - |
| Withdrew consent | - | - | - |
| Completed treatment as per protocol | - | - | - |
| Not completing monotherapy | - | - | - |

| Number of subjects in period 1 | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|------------------------------------|---------------------|------------------------|-------------------|
| Started | 19 | 31 | 15 |
| Continuing to Combo Therapy | 0 ^[8] | 0 ^[9] | 0 ^[10] |
| Crossing over to RCC combo therapy | 0 ^[11] | 0 ^[12] | 0 ^[13] |

| | | | |
|-------------------------------------|----|----|----|
| Completed | 2 | 11 | 1 |
| Not completed | 17 | 20 | 14 |
| Disease progression | 16 | 18 | 13 |
| Study drug toxicity | - | 2 | 1 |
| Request to discontinue | - | - | - |
| Maximum clinical benefit | - | - | - |
| AE unrelated to study drug | - | - | - |
| No longer meets study criteria | - | - | - |
| Other reasons | - | - | - |
| Withdrew consent | 1 | - | - |
| Completed treatment as per protocol | - | - | - |
| Not completing monotherapy | - | - | - |

| Number of subjects in period 1 | P2 Combo SCCHN | P2 RCC Monotherapy | P2 RCC Combo Therapy |
|---------------------------------------|-------------------|--------------------|----------------------|
| Started | 15 | 19 | 18 |
| Continuing to Combo Therapy | 0 ^[14] | 0 ^[15] | 0 ^[16] |
| Crossing over to RCC combo therapy | 0 ^[17] | 3 ^[18] | 0 ^[19] |
| Completed | 1 | 5 | 5 |
| Not completed | 14 | 14 | 13 |
| Disease progression | 10 | 12 | 12 |
| Study drug toxicity | 1 | - | - |
| Request to discontinue | - | 1 | 1 |
| Maximum clinical benefit | - | - | - |
| AE unrelated to study drug | - | - | - |
| No longer meets study criteria | - | - | - |
| Other reasons | 2 | - | - |
| Withdrew consent | - | - | - |
| Completed treatment as per protocol | 1 | - | - |
| Not completing monotherapy | - | 1 | - |

| Number of subjects in period 1 | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|---------------------------------------|-------------------|---------------------|---------------------------|
| Started | 14 | 2 | 1 |
| Continuing to Combo Therapy | 0 | 0 ^[20] | 0 |
| Crossing over to RCC combo therapy | 0 | 0 ^[21] | 0 |
| Completed | 0 | 2 | 0 |
| Not completed | 14 | 0 | 1 |
| Disease progression | 14 | - | 1 |
| Study drug toxicity | - | - | - |
| Request to discontinue | - | - | - |
| Maximum clinical benefit | - | - | - |

| | | | |
|-------------------------------------|---|---|---|
| AE unrelated to study drug | - | - | - |
| No longer meets study criteria | - | - | - |
| Other reasons | - | - | - |
| Withdrew consent | - | - | - |
| Completed treatment as per protocol | - | - | - |
| Not completing monotherapy | - | - | - |

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[7] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[8] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[9] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[10] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[11] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[12] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[13] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that

completed, minus those who left.

Justification: No subjects in this milestone for this arm

[14] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[15] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[16] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[17] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[18] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[19] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[20] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

[21] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: No subjects in this milestone for this arm

Baseline characteristics

| Reporting groups | |
|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Reporting group title | P1A 150mg |
| Reporting group description: BMS-986179 150mg monotherapy leading into BMS-986179 150mg + Nivo 240 combo therapy | |
| Reporting group title | P1A 300mg |
| Reporting group description: BMS-986179 300mg monotherapy leading into BMS-986179 300mg + Nivo 240mg combo therapy | |
| Reporting group title | P1A 600mg |
| Reporting group description: BMS-986179 600mg monotherapy leading into BMS-986179 600mg + Nivo 240mg combo therapy | |
| Reporting group title | P1A 1200mg |
| Reporting group description: BMS-986179 1200mg monotherapy leading into BMS-986179 1200mg + Nivo 240mg combo therapy | |
| Reporting group title | P1A 1600mg |
| Reporting group description: BMS-986179 1600mg monotherapy leading into BMS-986179 1600mg + Nivo 240mg combo therapy | |
| Reporting group title | P1B Combo Therapy 150mg |
| Reporting group description: BMS-986179 150mg + Nivo 360mg | |
| Reporting group title | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg |
| Reporting group description: BMS-986179 1200mg + Nivo 360mg | |
| Reporting group title | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
| Reporting group description: BMS-986179 1200mg + Nivo 480mg | |
| Reporting group title | P1B BMS986-179 1600mg |
| Reporting group description: BMS-986179 1600mg SC | |
| Reporting group title | P2 Combo Pancreatic |
| Reporting group description: BMS-986179 1200mg Q2W + Nivo 240mg Q2W | |
| Reporting group title | P2 Combo Therapy NSCLC |
| Reporting group description: BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Reporting group title | P2 Combo Melanoma |
| Reporting group description: BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Reporting group title | P2 Combo SCCHN |
| Reporting group description: BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Reporting group title | P2 RCC Monotherapy |
| Reporting group description: BMS-986179 600mg Q2W monotherapy | |
| Reporting group title | P2 RCC Combo Therapy |
| Reporting group description: BMS-986179 600mg Q2W + Nivo 480mg Q4W combo therapy | |
| Reporting group title | P2 Combo Prostate |
| Reporting group description: BMS-986179 600mg Q2W + Nivo 480mg Q4W | |

| | |
|------------------------------------------------------------------------|---------------------------|
| Reporting group title | P2 Combo Unassigned |
| Reporting group description: BMS-986179 1200mg Q2W + Nivo 240mg Q2W | |
| Reporting group title | P2 Monotherapy Unassigned |
| Reporting group description: BMS-986179 600mg Q2W | |

| Reporting group values | P1A 150mg | P1A 300mg | P1A 600mg |
|-------------------------------------------|-----------|-----------|-----------|
| Number of subjects | 14 | 12 | 12 |
| Age Categorical Units: Participants | | | |
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 9 | 10 |
| >=65 years | 7 | 3 | 2 |
| Sex: Female, Male Units: Participants | | | |
| Female | 8 | 5 | 2 |
| Male | 6 | 7 | 10 |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 14 | 11 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 0 | 1 | 0 |
| Not Hispanic or Latino | 5 | 4 | 6 |
| Unknown or Not Reported | 9 | 7 | 6 |

| Reporting group values | P1A 1200mg | P1A 1600mg | P1B Combo Therapy 150mg |
|------------------------------------------|------------|------------|----------------------------|
| Number of subjects | 9 | 12 | 9 |
| Age Categorical Units: Participants | | | |
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 7 | 5 |
| >=65 years | 4 | 5 | 4 |
| Sex: Female, Male Units: Participants | | | |
| Female | 3 | 7 | 7 |
| Male | 6 | 5 | 2 |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |

| | | | |
|-------------------------------------------|---|----|---|
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 8 | 12 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 5 | 4 |
| Unknown or Not Reported | 5 | 7 | 5 |

| Reporting group values | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg | P1B BMS986-179 1600mg |
|-------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------|
| Number of subjects | 8 | 7 | 18 |
| Age Categorical | | | |
| Units: Participants | | | |
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 5 | 11 |
| >=65 years | 1 | 2 | 7 |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 4 | 2 | 10 |
| Male | 4 | 5 | 8 |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 |
| White | 7 | 5 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 7 | 11 |
| Unknown or Not Reported | 5 | 0 | 7 |

| Reporting group values | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-------------------------------|------------------------|---------------------------|----------------------|
| Number of subjects | 19 | 31 | 15 |
| Age Categorical | | | |
| Units: Participants | | | |
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 14 | 8 |
| >=65 years | 5 | 17 | 7 |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 8 | 10 | 9 |
| Male | 11 | 21 | 6 |

| | | | |
|-------------------------------------------|----|----|----|
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 |
| White | 19 | 30 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 1 | 3 |
| Unknown or Not Reported | 8 | 30 | 12 |

| Reporting group values | P2 Combo SCCHN | P2 RCC Monotherapy | P2 RCC Combo Therapy |
|-------------------------------------------|----------------|--------------------|----------------------|
| Number of subjects | 15 | 19 | 18 |
| Age Categorical | | | |
| Units: Participants | | | |
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 12 | 12 |
| >=65 years | 9 | 7 | 6 |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 1 | 13 | 13 |
| Male | 14 | 6 | 5 |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | |
| White | 14 | 18 | 18 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 1 | 0 | 0 |
| Not Hispanic or Latino | 2 | 12 | 12 |
| Unknown or Not Reported | 12 | 7 | 6 |

| Reporting group values | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-------------------------|-------------------|---------------------|---------------------------|
| Number of subjects | 14 | 2 | 1 |
| Age Categorical | | | |
| Units: Participants | | | |
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 2 | 1 |
| >=65 years | 9 | 0 | 0 |

| | | | |
|-------------------------------------------|----|---|---|
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 0 | 0 | 0 |
| Male | 14 | 2 | 1 |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 13 | 1 | 1 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 2 | 0 |
| Unknown or Not Reported | 14 | 0 | 1 |

| | | | |
|-------------------------------------------|-------|--|--|
| Reporting group values | Total | | |
| Number of subjects | 235 | | |
| Age Categorical | | | |
| Units: Participants | | | |
| <=18 years | 0 | | |
| Between 18 and 65 years | 140 | | |
| >=65 years | 95 | | |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 102 | | |
| Male | 133 | | |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | | |
| Asian | 8 | | |
| Native Hawaiian or Other Pacific Islander | 0 | | |
| Black or African American | 5 | | |
| White | 218 | | |
| More than one race | 0 | | |
| Unknown or Not Reported | 4 | | |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 2 | | |
| Not Hispanic or Latino | 92 | | |
| Unknown or Not Reported | 141 | | |

Subject analysis sets

| | |
|----------------------------|--------------------|
| Subject analysis set title | P2 RCC Combo |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W combo therapy

| | |
|----------------------------|-------------------------|
| Subject analysis set title | P1A Combo Therapy 150mg |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

BMS-986179 150mg + Nivo 240mg

| | |
|----------------------------|-------------------------|
| Subject analysis set title | P1A Combo Therapy 300mg |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

BMS-986179 300mg + Nivo 240mg

| | |
|----------------------------|-------------------------|
| Subject analysis set title | P1A Combo Therapy 600mg |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

BMS-986179 600mg + Nivo 240mg

| | |
|----------------------------|--------------------------|
| Subject analysis set title | P1A Combo Therapy 1200mg |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

BMS-986179 1200mg + Nivo 240mg

| | |
|----------------------------|--------------------------|
| Subject analysis set title | P1A Combo Therapy 1600mg |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

BMS-986179 1600mg + Nivo 240mg

| | |
|----------------------------|------------------------|
| Subject analysis set title | P2 Combo RCC Crossover |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W

| Reporting group values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg |
|-------------------------------------------|--------------|-------------------------|-------------------------|
| Number of subjects | 18 | 12 | 11 |
| Age Categorical Units: Participants | | | |
| <=18 years | 0 | | |
| Between 18 and 65 years | 12 | | |
| >=65 years | 6 | | |
| Sex: Female, Male Units: Participants | | | |
| Female | 5 | | |
| Male | 13 | | |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native | 0 | | |
| Asian | 0 | | |
| Native Hawaiian or Other Pacific Islander | 0 | | |
| Black or African American | 0 | | |
| White | 18 | | |
| More than one race | 0 | | |
| Unknown or Not Reported | 0 | | |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 0 | | |

| | | | |
|-------------------------|----|--|--|
| Not Hispanic or Latino | 12 | | |
| Unknown or Not Reported | 6 | | |

| Reporting group values | P1A Combo Therapy 600mg | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg |
|----------------------------------------------|----------------------------|-----------------------------|-----------------------------|
| Number of subjects | 12 | 7 | 10 |
| Age Categorical Units: Participants | | | |
| <=18 years | | | |
| Between 18 and 65 years | | | |
| >=65 years | | | |
| Sex: Female, Male Units: Participants | | | |
| Female | | | |
| Male | | | |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native | | | |
| Asian | | | |
| Native Hawaiian or Other Pacific Islander | | | |
| Black or African American | | | |
| White | | | |
| More than one race | | | |
| Unknown or Not Reported | | | |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | | | |
| Not Hispanic or Latino | | | |
| Unknown or Not Reported | | | |

| Reporting group values | P2 Combo RCC Crossover | | |
|----------------------------------------------|---------------------------|--|--|
| Number of subjects | 3 | | |
| Age Categorical Units: Participants | | | |
| <=18 years | | | |
| Between 18 and 65 years | | | |
| >=65 years | | | |
| Sex: Female, Male Units: Participants | | | |
| Female | | | |
| Male | | | |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native | | | |
| Asian | | | |
| Native Hawaiian or Other Pacific Islander | | | |
| Black or African American | | | |
| White | | | |
| More than one race | | | |

| | | | |
|-------------------------|--|--|--|
| Unknown or Not Reported | | | |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | | | |
| Not Hispanic or Latino | | | |
| Unknown or Not Reported | | | |

End points

End points reporting groups

| | |
|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Reporting group title | P1A 150mg |
| Reporting group description: BMS-986179 150mg monotherapy leading into BMS-986179 150mg + Nivo 240 combo therapy | |
| Reporting group title | P1A 300mg |
| Reporting group description: BMS-986179 300mg monotherapy leading into BMS-986179 300mg + Nivo 240mg combo therapy | |
| Reporting group title | P1A 600mg |
| Reporting group description: BMS-986179 600mg monotherapy leading into BMS-986179 600mg + Nivo 240mg combo therapy | |
| Reporting group title | P1A 1200mg |
| Reporting group description: BMS-986179 1200mg monotherapy leading into BMS-986179 1200mg + Nivo 240mg combo therapy | |
| Reporting group title | P1A 1600mg |
| Reporting group description: BMS-986179 1600mg monotherapy leading into BMS-986179 1600mg + Nivo 240mg combo therapy | |
| Reporting group title | P1B Combo Therapy 150mg |
| Reporting group description: BMS-986179 150mg + Nivo 360mg | |
| Reporting group title | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg |
| Reporting group description: BMS-986179 1200mg + Nivo 360mg | |
| Reporting group title | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
| Reporting group description: BMS-986179 1200mg + Nivo 480mg | |
| Reporting group title | P1B BMS986-179 1600mg |
| Reporting group description: BMS-986179 1600mg SC | |
| Reporting group title | P2 Combo Pancreatic |
| Reporting group description: BMS-986179 1200mg Q2W + Nivo 240mg Q2W | |
| Reporting group title | P2 Combo Therapy NSCLC |
| Reporting group description: BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Reporting group title | P2 Combo Melanoma |
| Reporting group description: BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Reporting group title | P2 Combo SCCHN |
| Reporting group description: BMS-986179 600mg Q2W + Nivo 480mg Q4W | |
| Reporting group title | P2 RCC Monotherapy |
| Reporting group description: BMS-986179 600mg Q2W monotherapy | |
| Reporting group title | P2 RCC Combo Therapy |
| Reporting group description: BMS-986179 600mg Q2W + Nivo 480mg Q4W combo therapy | |
| Reporting group title | P2 Combo Prostate |

Reporting group description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W

| | |
|-----------------------|---------------------|
| Reporting group title | P2 Combo Unassigned |
|-----------------------|---------------------|

Reporting group description:

BMS-986179 1200mg Q2W + Nivo 240mg Q2W

| | |
|-----------------------|---------------------------|
| Reporting group title | P2 Monotherapy Unassigned |
|-----------------------|---------------------------|

Reporting group description:

BMS-986179 600mg Q2W

| | |
|----------------------------|--------------|
| Subject analysis set title | P2 RCC Combo |
|----------------------------|--------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W combo therapy

| | |
|----------------------------|-------------------------|
| Subject analysis set title | P1A Combo Therapy 150mg |
|----------------------------|-------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

BMS-986179 150mg + Nivo 240mg

| | |
|----------------------------|-------------------------|
| Subject analysis set title | P1A Combo Therapy 300mg |
|----------------------------|-------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

BMS-986179 300mg + Nivo 240mg

| | |
|----------------------------|-------------------------|
| Subject analysis set title | P1A Combo Therapy 600mg |
|----------------------------|-------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

BMS-986179 600mg + Nivo 240mg

| | |
|----------------------------|--------------------------|
| Subject analysis set title | P1A Combo Therapy 1200mg |
|----------------------------|--------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

BMS-986179 1200mg + Nivo 240mg

| | |
|----------------------------|--------------------------|
| Subject analysis set title | P1A Combo Therapy 1600mg |
|----------------------------|--------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

BMS-986179 1600mg + Nivo 240mg

| | |
|----------------------------|------------------------|
| Subject analysis set title | P2 Combo RCC Crossover |
|----------------------------|------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W

Primary: Number of participants with drug related AEs, SAEs, AEs leading to discontinuation and deaths.

| | |
|-----------------|------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with drug related AEs, SAEs, AEs leading to discontinuation and deaths. ^{[1][2]} |
|-----------------|------------------------------------------------------------------------------------------------------------------|

End point description:

Number of participants with drug related adverse events (AE), drug related serious adverse events (SAE), drug related AEs Leading to discontinuation and drug related deaths

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From first dose to 100 days post last dose: Part 1 up to 25.1 months, Part 2 SC up to 17.5 months, RCC Mono up to 28.1 months, Part 2 up to 27.2 months.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No subjects analyzed for this arm

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|--------------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 12 | 9 |
| Units: Participants | | | | |
| Adverse Events | 7 | 4 | 3 | 4 |
| Serious Adverse Events | 0 | 0 | 0 | 0 |
| AEs Leading to Discontinuation | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|--------------------------------|-----------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 9 | 8 | 7 |
| Units: Participants | | | | |
| Adverse Events | 5 | 5 | 1 | 2 |
| Serious Adverse Events | 0 | 0 | 0 | 0 |
| AEs Leading to Discontinuation | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|--------------------------------|-----------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 19 | 31 | 15 |
| Units: Participants | | | | |
| Adverse Events | 4 | 11 | 21 | 7 |
| Serious Adverse Events | 0 | 0 | 1 | 1 |
| AEs Leading to Discontinuation | 0 | 0 | 2 | 1 |
| Deaths | 0 | 0 | 0 | 0 |

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|--------------------------------|-----------------|-------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 14 | 2 | 1 |
| Units: Participants | | | | |
| Adverse Events | 12 | 8 | 1 | 0 |
| Serious Adverse Events | 1 | 0 | 0 | 0 |
| AEs Leading to Discontinuation | 1 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|--------------------------------|----------------------|-------------------------|-------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 18 | 12 | 11 | 12 |
| Units: Participants | | | | |
| Adverse Events | 15 | 7 | 7 | 6 |
| Serious Adverse Events | 1 | 2 | 0 | 1 |
| AEs Leading to Discontinuation | 0 | 2 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|--------------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 3 | |
| Units: Participants | | | | |
| Adverse Events | 5 | 7 | 3 | |
| Serious Adverse Events | 0 | 1 | 0 | |
| AEs Leading to Discontinuation | 0 | 0 | 0 | |
| Deaths | 0 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with a best overall response (BOR) at week 24

| | |
|-----------------|-------------------------------------------------------------------------------------|
| End point title | Number of participants with a best overall response (BOR) at week 24 ^[3] |
|-----------------|-------------------------------------------------------------------------------------|

End point description:

Best overall response (BOR) is defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy. CR or PR determinations included in the BOR assessment must be confirmed by a second scan performed no less than 4 weeks after the criteria for response are first met.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from initial treatment to week 24

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-----------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 12 | 9 |
| Units: Participants | | | | |
| Complete Response | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 0 | 0 | 0 |

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-----------------------------|-----------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 9 | 8 | 7 |
| Units: Participants | | | | |
| Complete Response | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 0 | 0 | 0 |

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-----------------------------|-----------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 19 | 31 | 15 |
| Units: Participants | | | | |
| Complete Response | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 1 | 1 | 0 |

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-----------------------------|-----------------|-------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 14 | 2 | 1 |
| Units: Participants | | | | |
| Complete Response | 1 | 0 | 0 | 0 |
| Partial Response | 1 | 0 | 0 | 0 |

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|-----------------------------|----------------------|-------------------------|-------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 18 | 12 | 11 | 12 |
| Units: Participants | | | | |
| Complete Response | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 1 | 1 | 2 |

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|-----------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 3 | |
| Units: Participants | | | | |
| Complete Response | 0 | 0 | 0 | |
| Partial Response | 1 | 1 | 0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with an objective response rate (ORR) at week 24

| | |
|-----------------|--------------------------------------------------------------------------------------------|
| End point title | Percentage of participants with an objective response rate (ORR) at week 24 ^[4] |
|-----------------|--------------------------------------------------------------------------------------------|

End point description:

ORR is defined as the percentage of all treated participants whose BOR is either a CR or PR.

Here "99999 and -99999" means not available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from initial treatment to week 24

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-----------------------------------|-----------------|-----------------|---------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 12 | 9 |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 0 (0.0 to 84.2) | 0 (0.0 to 97.5) | 0 (-99999 to 99999) | 0 (-99999 to 99999) |

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-----------------------------------|-----------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 9 | 8 | 7 |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 0 (0.0 to 84.2) | 0 (0.0 to 33.6) | 0 (0.0 to 36.9) | 0 (0.0 to 41.0) |

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-----------------------------------|-----------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 19 | 31 | 15 |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 0 (0.0 to 18.5) | 5.3 (0.1 to 26.0) | 3.2 (0.1 to 16.7) | 0 (0.0 to 21.8) |

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-----------------------------------|--------------------|-------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 14 | 2 | 1 |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 13.3 (1.7 to 40.5) | 0 (0.0 to 23.2) | 0 (0.0 to 84.2) | 0 (0.0 to 97.5) |

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|-----------------------------------|----------------------|-------------------------|-------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 18 | 12 | 11 | 12 |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 0 (0.0 to 18.5) | 8.3 (0.2 to 38.5) | 9.1 (0.2 to 41.3) | 16.7 (2.1 to 48.4) |

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|-----------------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 3 | |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 14.3 (0.4 to 57.9) | 10.0 (0.3 to 44.5) | 0 (0.0 to 70.8) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Progression free survival rate (PFSR) at week 24

| | |
|-----------------|-----------------------------------------------------------------|
| End point title | Progression free survival rate (PFSR) at week 24 ^[5] |
|-----------------|-----------------------------------------------------------------|

End point description:

PFSR at 24 weeks is defined as the percentage of treated participants remaining progression free and surviving at 24 weeks.

Here "99999 and -99999" means not available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from initial treatment to week 24

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|----------------------------------|-------------------|--------------------|---------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 12 | 9 |
| Units: Percentage | | | | |
| number (confidence interval 95%) | 7.1 (1.3 to 98.7) | 8.3 (2.5 to 100.0) | 0 (-99999 to 99999) | 11.1 (1.3 to 98.7) |

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|----------------------------------|----------------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 9 | 8 | 7 |
| Units: Percentage | | | | |
| number (confidence interval 95%) | 16.7 (15.8 to 100.0) | 88.9 (51.8 to 99.7) | 87.5 (47.3 to 99.7) | 100.00 (59.0 to 100.0) |

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|----------------------------------|-----------------------|---------------------|------------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 19 | 31 | 15 |
| Units: Percentage | | | | |
| number (confidence interval 95%) | 88.9 (65.3 to 98.6) | 94.7 (74.0 to 99.9) | 71.0 (52.0 to 85.8) | 86.7 (59.5 to 98.3) |

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|----------------------------------|---------------------|---------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 14 | 2 | 1 |
| Units: Percentage | | | | |
| number (confidence interval 95%) | 80.0 (51.9 to 95.7) | 71.4 (41.9 to 91.6) | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) |

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|----------------------------------|----------------------|-------------------------|-------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 18 | 12 | 11 | 12 |
| Units: Percentage | | | | |
| number (confidence interval 95%) | 72.2 (46.5 to 90.3) | 83.3 (51.6 to 97.9) | 72.7 (39.0 to 94.0) | 75.0 (42.8 to 94.5) |

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|----------------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 3 | |
| Units: Percentage | | | | |
| number (confidence interval 95%) | 57.1 (18.4 to 90.1) | 70.0 (34.8 to 93.3) | 66.7 (9.4 to 99.2) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Median duration of response (DOR)

| | |
|-----------------|--------------------------------------------------|
| End point title | Median duration of response (DOR) ^[6] |
|-----------------|--------------------------------------------------|

End point description:

DOR (computed for all treated subjects with a BOR of CR or PR) is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first.

Here "99999 and -99999" means not available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from first measure response approximately up to 25 months

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 12 | 9 |
| Units: Months | | | | |
| median (full range (min-max)) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) |

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-------------------------------|-------------------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 9 | 8 | 7 |
| Units: Months | | | | |
| median (full range (min-max)) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) |

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-------------------------------|-------------------------|---------------------|------------------------|-------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 19 | 31 | 15 |
| Units: Months | | | | |
| median (full range (min-max)) | 99999 (-99999 to 99999) | 3.90 (3.9 to 3.9) | 3.80 (3.8 to 3.8) | 99999 (-99999 to 99999) |

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-------------------------------|-------------------|-------------------------|-------------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 14 | 2 | 1 |
| Units: Months | | | | |
| median (full range (min-max)) | 6.70 (3.8 to 9.6) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) | 99999 (-99999 to 99999) |

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|-------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 18 | 12 | 11 | 12 |
| Units: Months | | | | |
| median (full range (min-max)) | 99999 (-99999 to 99999) | 17.40 (17.4 to 17.4) | 5.70 (5.7 to 5.7) | 9.30 (7.2 to 11.4) |

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|-----------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 3 | |

| | | | | |
|-------------------------------|-------------------|----------------------|------------------------|--|
| Units: Months | | | | |
| median (full range (min-max)) | 2.10 (2.1 to 2.1) | 24.40 (24.4 to 24.4) | 99999 (99999 to 99999) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cmax

| | |
|-----------------|---------------------|
| End point title | Cmax ^[7] |
|-----------------|---------------------|

End point description:

Cmax is defined as maximum plasma concentration of the drug

Here "99999 and -99999" means not available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1A Cycle 0 = 14 days Cycle 1 = 28 days Part 1B and Part 2 Q2W regimen Cycle 0 = 14 days Cycle 1 = 28 days Cycle 2 = 28 days Part 1B and 2 Q4W Regimen Cycle 1= 28 days Cycle 2 = 28 days Cycle 4 = 28 days

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-----------------------------------------------------|-----------------|----------------------|------------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 0 ^[8] | 9 |
| Units: ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 30.6524 (± 66) | 94.9210 (± 99999) | () | 218.0423 (± 8) |
| Cycle 1 Day 1 | 99999 (± 99999) | 9999999999 (± 99999) | () | 99999 (± 99999) |
| Cycle 1 Day 22 | 99999 (± 99999) | 99999 (± 99999) | () | 99999 (± 99999) |
| Cycle 2 Day 1 | 99999 (± 99999) | 99999 (± 99999) | () | 99999 (± 99999) |
| cycle 4 Day 15 | 99999 (± 99999) | 99999 (± 99999) | () | 99999 (± 99999) |

Notes:

[8] - No subjects analyzed

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-----------------------------------------------------|-----------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 0 ^[9] | 0 ^[10] | 0 ^[11] |
| Units: ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |

| | | | | |
|----------------|----------------------|----|----|----|
| Cycle 0 Day 1 | 499.5178 (\pm 10) | () | () | () |
| Cycle 1 Day 1 | 99999 (\pm 99999) | () | () | () |
| Cycle 1 Day 22 | 99999 (\pm 99999) | () | () | () |
| Cycle 2 Day 1 | 99999 (\pm 99999) | () | () | () |
| cycle 4 Day 15 | 99999 (\pm 99999) | () | () | () |

Notes:

[9] - No subjects analyzed

[10] - No subjects analyzed

[11] - No subjects analyzed

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-----------------------------------------------------|-----------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 0 ^[12] | 0 ^[13] | 0 ^[14] |
| Units: ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 99999 (\pm 99999) | () | () | () |
| Cycle 1 Day 1 | 93.7415 (\pm 33) | () | () | () |
| Cycle 1 Day 22 | 99999 (\pm 99999) | () | () | () |
| Cycle 2 Day 1 | 563.4487 (\pm 27) | () | () | () |
| cycle 4 Day 15 | 99999 (\pm 99999) | () | () | () |

Notes:

[12] - No subjects analyzed

[13] - No subjects analyzed

[14] - No subjects analyzed

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-----------------------------------------------------|-------------------|-------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[15] | 0 ^[16] | 0 ^[17] | 0 ^[18] |
| Units: ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | () | () | () | () |
| Cycle 1 Day 1 | () | () | () | () |
| Cycle 1 Day 22 | () | () | () | () |
| Cycle 2 Day 1 | () | () | () | () |
| cycle 4 Day 15 | () | () | () | () |

Notes:

[15] - No subjects analyzed

[16] - No subjects analyzed

[17] - No subjects analyzed

[18] - No subjects analyzed

| End point values | P2 RCC Combo | P1A Combo Therapy | P1A Combo Therapy | P1A Combo Therapy |
|------------------|--------------|-------------------|-------------------|-------------------|
|------------------|--------------|-------------------|-------------------|-------------------|

| | | 150mg | 300mg | 600mg |
|-----------------------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[19] | 12 | 11 | 12 |
| Units: ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | () | 28.8892 (± 25) | 64.3400 (± 55) | 141.3732 (± 26) |
| Cycle 1 Day 1 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| Cycle 1 Day 22 | () | 51.3637 (± 38) | 99.3564 (± 47) | 289.8829 (± 27) |
| Cycle 2 Day 1 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| cycle 4 Day 15 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |

Notes:

[19] - No subjects analyzed

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|-----------------------------------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 0 ^[20] | |
| Units: ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 315.6963 (± 16) | 453.5664 (± 27) | () | |
| Cycle 1 Day 1 | 99999 (± 99999) | 99999 (± 99999) | () | |
| Cycle 1 Day 22 | 722.2768 (± 32) | 865.8497 (± 22) | () | |
| Cycle 2 Day 1 | 99999 (± 99999) | 99999 (± 99999) | () | |
| cycle 4 Day 15 | 99999 (± 99999) | 99999 (± 99999) | () | |

Notes:

[20] - No subjects analyzed

Statistical analyses

No statistical analyses for this end point

Secondary: Tmax

End point title Tmax^[21]

End point description:

Tmax is defined is the time to maximum plasma concentration

Here "99999 and -99999" means not available

End point type Secondary

End point timeframe:

Part 1A Cycle 0 = 14 days Cycle 1 = 28 days Part 1B and Part 2 Q2W regimen Cycle 0 = 14 days Cycle 1 = 28 days Cycle 2 = 28 days Part 1B and 2 Q4W Regimen Cycle 1= 28 days Cycle 2 = 28 days Cycle 4 = 28 days

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-------------------------------|------------------------|------------------------|-------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 0 ^[22] | 9 |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Cycle 0 Day 1 | 2.409 (0.800 to 4.017) | 0.933 (0.933 to 0.933) | (to) | 2.992 (1.983 to 4.00) |
| Cycle 1 Day 1 | 99999 (99999 to 99999) | 99999 (99999 to 99999) | (to) | 99999 (99999 to 99999) |
| Cycle 1 Day 22 | 99999 (99999 to 99999) | 99999 (99999 to 99999) | (to) | 99999 (99999 to 99999) |
| Cycle 2 Day 1 | 99999 (99999 to 99999) | 99999 (99999 to 99999) | (to) | 99999 (99999 to 99999) |
| cycle 4 Day 15 | 99999 (99999 to 99999) | 99999 (99999 to 99999) | (to) | 99999 (99999 to 99999) |

Notes:

[22] - no subjects analyzed

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-------------------------------|------------------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 0 ^[23] | 0 ^[24] | 0 ^[25] |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Cycle 0 Day 1 | 2.700 (2.400 to 3.00) | (to) | (to) | (to) |
| Cycle 1 Day 1 | 99999 (99999 to 99999) | (to) | (to) | (to) |
| Cycle 1 Day 22 | 99999 (99999 to 99999) | (to) | (to) | (to) |
| Cycle 2 Day 1 | 99999 (99999 to 99999) | (to) | (to) | (to) |
| cycle 4 Day 15 | 99999 (99999 to 99999) | (to) | (to) | (to) |

Notes:

[23] - no subjects analyzed

[24] - no subjects analyzed

[25] - no subjects analyzed

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-------------------------------|------------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 0 ^[26] | 0 ^[27] | 0 ^[28] |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Cycle 0 Day 1 | 99999 (99999 to 99999) | (to) | (to) | (to) |

| | | | | |
|----------------|----------------------------|--------|--------|--------|
| Cycle 1 Day 1 | 96.200 (48.017 to 168.267) | (to) | (to) | (to) |
| Cycle 1 Day 22 | 99999 (99999 to 99999) | (to) | (to) | (to) |
| Cycle 2 Day 1 | 4.000 (1.967 to 24.667) | (to) | (to) | (to) |
| cycle 4 Day 15 | 99999 (99999 to 99999) | (to) | (to) | (to) |

Notes:

[26] - no subjects analyzed

[27] - no subjects analyzed

[28] - no subjects analyzed

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-------------------------------|-------------------|----------------------|------------------------|---------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[29] | 0 ^[30] | 0 ^[31] | 0 ^[32] |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Cycle 0 Day 1 | (to) | (to) | (to) | (to) |
| Cycle 1 Day 1 | (to) | (to) | (to) | (to) |
| Cycle 1 Day 22 | (to) | (to) | (to) | (to) |
| Cycle 2 Day 1 | (to) | (to) | (to) | (to) |
| cycle 4 Day 15 | (to) | (to) | (to) | (to) |

Notes:

[29] - no subjects analyzed

[30] - no subjects analyzed

[31] - no subjects analyzed

[32] - no subjects analyzed

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|-------------------------------|----------------------|-------------------------------|-------------------------------|-------------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[33] | 12 | 11 | 12 |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Cycle 0 Day 1 | (to) | 1.00 (0.967 to 8.250) | 2.942 (0.967 to 8.00) | 1.109 (0.867 to 24.050) |
| Cycle 1 Day 1 | (to) | 99999 (99999 to 99999) | 99999 (99999 to 99999) | 99999 (99999 to 99999) |
| Cycle 1 Day 22 | (to) | 4.000 (0.967 to 9.050) | 7.767 (4.067 to 95.950) | 4.000 (0.967 to 7.933) |
| Cycle 2 Day 1 | (to) | 99999 (99999 to 99999) | 99999 (99999 to 99999) | 99999 (99999 to 99999) |
| cycle 4 Day 15 | (to) | 99999 (99999 to 99999) | 99999 (99999 to 99999) | 99999 (99999 to 99999) |

Notes:

[33] - no subjects analyzed

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|------------------|--------------------------------|--------------------------------|---------------------------|--|
|------------------|--------------------------------|--------------------------------|---------------------------|--|

| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
|-------------------------------|-------------------------|-------------------------|----------------------|--|
| Number of subjects analysed | 7 | 10 | 0 ^[34] | |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Cycle 0 Day 1 | 4.000 (1.967 to 8.000) | 3.692 (1.783 to 24.117) | (to) | |
| Cycle 1 Day 1 | 99999 (99999 to 99999) | 99999 (99999 to 99999) | (to) | |
| Cycle 1 Day 22 | 8.000 (2.100 to 10.050) | 4.000 (1.983 to 8.000) | (to) | |
| Cycle 2 Day 1 | 99999 (99999 to 99999) | 99999 (99999 to 99999) | (to) | |
| cycle 4 Day 15 | 99999 (99999 to 99999) | 99999 (99999 to 99999) | (to) | |

Notes:

[34] - no subjects analyzed

Statistical analyses

No statistical analyses for this end point

Secondary: AUC (0-T)

| | |
|-----------------|---------------------------|
| End point title | AUC (0-T) ^[35] |
|-----------------|---------------------------|

End point description:

Area under the plasma concentration time-curve. AUC from time 0 to the last time of quantifiable concentration

Here "99999 and -99999" means not available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1A Cycle 0 = 14 days Cycle 1 = 28 days Part 1B and Part 2 Q2W regimen Cycle 0 = 14 days Cycle 1 = 28 days Cycle 2 = 28 days Part 1B and 2 Q4W Regimen Cycle 1= 28 days Cycle 2 = 28 days Cycle 4 = 28 days

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-----------------------------------------------------|------------------|---------------------|-------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 0 ^[36] | 9 |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 1414.4834 (± 76) | 2565.0489 (± 99999) | () | 9362.9155 (± 39) |
| Cycle 1 Day 1 | 99999 (± 99999) | 99999 (± 99999) | () | 99999 (± 99999) |
| Cycle 1 Day 22 | 99999 (± 99999) | 99999 (± 99999) | () | 99999 (± 99999) |
| Cycle 2 Day 1 | 99999 (± 99999) | 99999 (± 99999) | () | 99999 (± 99999) |
| cycle 4 Day 15 | 99999 (± 99999) | 99999 (± 99999) | () | 99999 (± 99999) |

Notes:

[36] - no subjects analyzed

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-----------------------------------------------------|-------------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 0 ^[37] | 0 ^[38] | 0 ^[39] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 30716.0037 (± 47) | () | () | () |
| Cycle 1 Day 1 | 99999 (± 99999) | () | () | () |
| Cycle 1 Day 22 | 99999 (± 99999) | () | () | () |
| Cycle 2 Day 1 | 99999 (± 99999) | () | () | () |
| cycle 4 Day 15 | 99999 (± 99999) | () | () | () |

Notes:

[37] - no subjects analyzed

[38] - no subjects analyzed

[39] - no subjects analyzed

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-----------------------------------------------------|-----------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 0 ^[40] | 0 ^[41] | 0 ^[42] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 99999 (± 99999) | () | () | () |
| Cycle 1 Day 1 | 41672.2787 (± 35) | () | () | () |
| Cycle 1 Day 22 | 99999 (± 99999) | () | () | () |
| Cycle 2 Day 1 | 84384.9379 (± 36) | () | () | () |
| cycle 4 Day 15 | 99999 (± 99999) | () | () | () |

Notes:

[40] - no subjects analyzed

[41] - no subjects analyzed

[42] - no subjects analyzed

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-----------------------------------------------------|-------------------|-------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[43] | 0 ^[44] | 0 ^[45] | 0 ^[46] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |

| | | | | |
|----------------|----|----|----|----|
| Cycle 0 Day 1 | () | () | () | () |
| Cycle 1 Day 1 | () | () | () | () |
| Cycle 1 Day 22 | () | () | () | () |
| Cycle 2 Day 1 | () | () | () | () |
| cycle 4 Day 15 | () | () | () | () |

Notes:

[43] - no subjects analyzed

[44] - no subjects analyzed

[45] - no subjects analyzed

[46] - no subjects analyzed

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|-----------------------------------------------------|----------------------|-------------------------|-------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[47] | 12 | 11 | 12 |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | () | 1225.3679 (± 36) | 3418.8393 (± 62) | 9139.4853 (± 30) |
| Cycle 1 Day 1 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| Cycle 1 Day 22 | () | 3932.5889 (± 44) | 9622.5237 (± 58) | 27616.4807 (± 40) |
| Cycle 2 Day 1 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| cycle 4 Day 15 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |

Notes:

[47] - no subjects analyzed

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|-----------------------------------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 0 ^[48] | |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 23533.0706 (± 9) | 31057.8588 (± 26) | () | |
| Cycle 1 Day 1 | 99999 (± 99999) | 99999 (± 99999) | () | |
| Cycle 1 Day 22 | 74405.3428 (± 25) | 92340.2959 (± 21) | () | |
| Cycle 2 Day 1 | 99999 (± 99999) | 99999 (± 99999) | () | |
| cycle 4 Day 15 | 99999 (± 99999) | 99999 (± 99999) | () | |

Notes:

[48] - no subjects analyzed

Statistical analyses

Secondary: AUC (Tau)

| | |
|-----------------|---------------------------|
| End point title | AUC (Tau) ^[49] |
|-----------------|---------------------------|

End point description:

Area under the plasma concentration time-curve. AUC over the dosing interval.

Here "99999 and -99999" means not available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1A Cycle 0 = 14 days Cycle 1 = 28 days Part 1B and Part 2 Q2W regimen Cycle 0 = 14 days Cycle 1 = 28 days Cycle 2 = 28 days Part 1B and 2 Q4W Regimen Cycle 1 = 28 days Cycle 2 = 28 days Cycle 4 = 28 days

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-----------------------------------------------------|------------------|-------------------|-------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 0 ^[50] | 0 ^[51] | 0 ^[52] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 1417.4834 (± 76) | () | () | () |
| Cycle 1 Day 1 | 99999 (± 99999) | () | () | () |
| Cycle 1 Day 22 | 99999 (± 99999) | () | () | () |
| Cycle 2 Day 1 | 99999 (± 99999) | () | () | () |
| cycle 4 Day 15 | 99999 (± 99999) | () | () | () |

Notes:

[50] - No subjects analyzed

[51] - No subjects analyzed

[52] - No subjects analyzed

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-----------------------------------------------------|-------------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 0 ^[53] | 0 ^[54] | 0 ^[55] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 34198.6293 (± 33) | () | () | () |
| Cycle 1 Day 1 | 99999 (± 99999) | () | () | () |
| Cycle 1 Day 22 | 99999 (± 99999) | () | () | () |

| | | | | |
|----------------|-----------------|----|----|----|
| Cycle 2 Day 1 | 99999 (± 99999) | () | () | () |
| cycle 4 Day 15 | 99999 (± 99999) | () | () | () |

Notes:

[53] - No subjects analyzed

[54] - No subjects analyzed

[55] - No subjects analyzed

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-----------------------------------------------------|-----------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 0 ^[56] | 0 ^[57] | 0 ^[58] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 99999 (± 99999) | () | () | () |
| Cycle 1 Day 1 | 40833.1977 (± 36) | () | () | () |
| Cycle 1 Day 22 | 99999 (± 99999) | () | () | () |
| Cycle 2 Day 1 | 92770.2634 (± 30) | () | () | () |
| cycle 4 Day 15 | 99999 (± 99999) | () | () | () |

Notes:

[56] - No subjects analyzed

[57] - No subjects analyzed

[58] - No subjects analyzed

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-----------------------------------------------------|-------------------|-------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[59] | 0 ^[60] | 0 ^[61] | 0 ^[62] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | () | () | () | () |
| Cycle 1 Day 1 | () | () | () | () |
| Cycle 1 Day 22 | () | () | () | () |
| Cycle 2 Day 1 | () | () | () | () |
| cycle 4 Day 15 | () | () | () | () |

Notes:

[59] - No subjects analyzed

[60] - No subjects analyzed

[61] - No subjects analyzed

[62] - No subjects analyzed

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|---------------------------------------|----------------------|-------------------------|-------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[63] | 12 | 11 | 12 |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient | | | | |

| | | | | |
|----------------|----|------------------|-------------------|-------------------|
| of variation) | | | | |
| Cycle 0 Day 1 | () | 1307.7132 (± 33) | 3546.1659 (± 59) | 9139.4853 (± 30) |
| Cycle 1 Day 1 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| Cycle 1 Day 22 | () | 3975.0900 (± 46) | 12326.2351 (± 44) | 30044.3813 (± 35) |
| Cycle 2 Day 1 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| cycle 4 Day 15 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |

Notes:

[63] - No subjects analyzed

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|-----------------------------------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 0 ^[64] | |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 23533.0706 (± 9) | 34970.3626 (± 12) | () | |
| Cycle 1 Day 1 | 99999 (± 99999) | 99999 (± 99999) | () | |
| Cycle 1 Day 22 | 74405.3428 (± 25) | 92340.2959 (± 21) | () | |
| Cycle 2 Day 1 | 99999 (± 99999) | 99999 (± 99999) | () | |
| cycle 4 Day 15 | 99999 (± 99999) | 99999 (± 99999) | () | |

Notes:

[64] - No subjects analyzed

Statistical analyses

No statistical analyses for this end point

Secondary: Ctau

| | |
|-----------------|----------------------|
| End point title | Ctau ^[65] |
|-----------------|----------------------|

End point description:

Ctau is defined as the concentration of study drug at the end of the dosing interval.

Here "99999 and -99999" means not available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Part 1A Cycle 0 = 14 days Cycle 1 = 28 days Part 1B and Part 2 Q2W regimen Cycle 0 = 14 days Cycle 1 = 28 days Cycle 2 = 28 days Part 1B and 2 Q4W Regimen Cycle 1 = 28 days Cycle 2 = 28 days Cycle 4 = 28 days

Notes:

[65] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-----------------------------------------------------|-----------------|-------------------|-------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 0 ^[66] | 0 ^[67] | 0 ^[68] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 1.9173 (± 99) | () | () | () |
| Cycle 1 Day 1 | 99999 (± 99999) | () | () | () |
| Cycle 1 Day 22 | 99999 (± 99999) | () | () | () |
| Cycle 2 Day 1 | 99999 (± 99999) | () | () | () |
| cycle 4 Day 15 | 99999 (± 99999) | () | () | () |

Notes:

[66] - No Subjects Analyzed

[67] - No Subjects Analyzed

[68] - No Subjects Analyzed

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-----------------------------------------------------|-----------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 0 ^[69] | 0 ^[70] | 0 ^[71] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 82.2225 (± 82) | () | () | () |
| Cycle 1 Day 1 | 99999 (± 99999) | () | () | () |
| Cycle 1 Day 22 | 99999 (± 99999) | () | () | () |
| Cycle 2 Day 1 | 99999 (± 99999) | () | () | () |
| cycle 4 Day 15 | 99999 (± 99999) | () | () | () |

Notes:

[69] - No Subjects Analyzed

[70] - No Subjects Analyzed

[71] - No Subjects Analyzed

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-----------------------------------------------------|-----------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 0 ^[72] | 0 ^[73] | 0 ^[74] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 99999 (± 99999) | () | () | () |
| Cycle 1 Day 1 | 30.0008 (± 51) | () | () | () |
| Cycle 1 Day 22 | 99999 (± 99999) | () | () | () |
| Cycle 2 Day 1 | 52.9049 (± 71) | () | () | () |

| | | | | |
|----------------|-----------------|----|----|----|
| cycle 4 Day 15 | 99999 (± 99999) | () | () | () |
|----------------|-----------------|----|----|----|

Notes:

[72] - No Subjects Analyzed

[73] - No Subjects Analyzed

[74] - No Subjects Analyzed

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-----------------------------------------------------|-------------------|-------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[75] | 0 ^[76] | 0 ^[77] | 0 ^[78] |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | () | () | () | () |
| Cycle 1 Day 1 | () | () | () | () |
| Cycle 1 Day 22 | () | () | () | () |
| Cycle 2 Day 1 | () | () | () | () |
| cycle 4 Day 15 | () | () | () | () |

Notes:

[75] - No Subjects Analyzed

[76] - No Subjects Analyzed

[77] - No Subjects Analyzed

[78] - No Subjects Analyzed

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|-----------------------------------------------------|----------------------|-------------------------|-------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[79] | 12 | 11 | 12 |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | () | 0.8999 (± 74) | 5.4691 (± 59) | 25.9755 (± 32) |
| Cycle 1 Day 1 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| Cycle 1 Day 22 | () | 14.5545 (± 54) | 51.0567 (± 44) | 126.4960 (± 37) |
| Cycle 2 Day 1 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| cycle 4 Day 15 | () | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |

Notes:

[79] - No Subjects Analyzed

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|-----------------------------------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 0 ^[80] | |
| Units: h*ug/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 0 Day 1 | 74.8859 (± 30) | 99.0307 (± 14) | () | |

| | | | | |
|----------------|----------------------|----------------------|----|--|
| Cycle 1 Day 1 | 99999 (\pm 99999) | 99999 (\pm 99999) | () | |
| Cycle 1 Day 22 | 366.8165 (\pm 21) | 466.5231 (\pm 32) | () | |
| Cycle 2 Day 1 | 99999 (\pm 99999) | 99999 (\pm 99999) | () | |
| cycle 4 Day 15 | 99999 (\pm 99999) | 99999 (\pm 99999) | () | |

Notes:

[80] - No Subjects Analyzed

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from baseline in CD73 assays

| | |
|-----------------|----------------------------------------------------------|
| End point title | Mean change from baseline in CD73 assays ^[81] |
|-----------------|----------------------------------------------------------|

End point description:

Mean change from baseline in CD73 assays at the end of Part 1A treatment period

Assays Measured:

EHC CD73 H-score

IHC CD73 Cytoplasm H-Score

IHC CDS73 Membrane H-Score

Here "99999 and -99999" means not available

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

approximately up to 95 weeks

Notes:

[81] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-------------------------------------------------------------------|--------------------------|---------------------------|-------------------|-------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 0 ^[82] | 9 |
| Units: mean change from baseline arithmetic mean (standard error) | | | | |
| EHC CD73 H-Score | -33.790 (\pm 25.5200) | -103.700 (\pm 90.3400) | () | -204.710 (\pm 99999) |
| IHC CD73 Cytoplasm H-Score | 1.5 (\pm 2.60) | -0.3 (\pm 32.04) | () | 17.0 (\pm 99999) |
| IHC CD73 Membrane H-Score | 7.3 (\pm 6.77) | 8.7 (\pm 30.33) | () | 88.0 (\pm 99999) |

Notes:

[82] - No subjects analyzed

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-------------------------------------------------------------------|-----------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 0 ^[83] | 0 ^[84] | 0 ^[85] |
| Units: mean change from baseline arithmetic mean (standard error) | | | | |

| | | | | |
|----------------------------|-------------------------|----|----|----|
| EHC CD73 H-Score | -3.220 (\pm 51.7800) | () | () | () |
| IHC CD73 Cytoplasm H-Score | 0.0 (\pm 0.00) | () | () | () |
| IHC CD73 Membrane H-Score | 0.00 (\pm 0.00) | () | () | () |

Notes:

[83] - No subjects analyzed

[84] - No subjects analyzed

[85] - No subjects analyzed

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|----------------------------------|-----------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[86] | 0 ^[87] | 0 ^[88] | 0 ^[89] |
| Units: mean change from baseline | | | | |
| arithmetic mean (standard error) | | | | |
| EHC CD73 H-Score | () | () | () | () |
| IHC CD73 Cytoplasm H-Score | () | () | () | () |
| IHC CD73 Membrane H-Score | () | () | () | () |

Notes:

[86] - No subjects analyzed

[87] - No subjects analyzed

[88] - No subjects analyzed

[89] - No subjects analyzed

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|----------------------------------|-------------------|-------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[90] | 0 ^[91] | 0 ^[92] | 0 ^[93] |
| Units: mean change from baseline | | | | |
| arithmetic mean (standard error) | | | | |
| EHC CD73 H-Score | () | () | () | () |
| IHC CD73 Cytoplasm H-Score | () | () | () | () |
| IHC CD73 Membrane H-Score | () | () | () | () |

Notes:

[90] - No subjects analyzed

[91] - No subjects analyzed

[92] - No subjects analyzed

[93] - No subjects analyzed

| End point values | P2 RCC Combo | P1A Combo Therapy 150mg | P1A Combo Therapy 300mg | P1A Combo Therapy 600mg |
|----------------------------------|----------------------|--------------------------|---------------------------|-------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[94] | 12 | 11 | 0 ^[95] |
| Units: mean change from baseline | | | | |
| arithmetic mean (standard error) | | | | |
| EHC CD73 H-Score | () | -33.790 (\pm 28.5200) | -103.700 (\pm 90.3400) | () |
| IHC CD73 Cytoplasm H-Score | () | 1.5 (\pm 2.60) | -0.3 (\pm 32.04) | () |
| IHC CD73 Membrane H-Score | () | 7.3 (\pm 6.77) | 8.7 (\pm 30.33) | () |

Notes:

[94] - No subjects analyzed

[95] - No subjects analyzed

| End point values | P1A Combo Therapy 1200mg | P1A Combo Therapy 1600mg | P2 Combo RCC Crossover | |
|----------------------------------|--------------------------|--------------------------|------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 7 | 10 | 0 ^[96] | |
| Units: mean change from baseline | | | | |
| arithmetic mean (standard error) | | | | |
| EHC CD73 H-Score | -204.710 (± 99999) | -3.220 (± 51.7800) | () | |
| IHC CD73 Cytoplasm H-Score | 17.0 (± 99999) | 0.0 (± 0.00) | () | |
| IHC CD73 Membrane H-Score | 88.0 (± 99999) | 0.0 (± 0.00) | () | |

Notes:

[96] - No subjects analyzed

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with a positive anti-drug antibody (ADA) test.

| | |
|-----------------|---------------------------------------------------------------------------------------|
| End point title | Number of participants with a positive anti-drug antibody (ADA) test. ^[97] |
|-----------------|---------------------------------------------------------------------------------------|

End point description:

A participant with at least one ADA-positive sample relative to baseline at any time after initiation of treatment with BMS-986179 and nivolumab.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From first dose to last dose: Part 1: up to 95 weeks, Part 2 SC: up to 62 weeks, RCC Mono: up to 108 weeks, Part 2: up to 104 weeks

Notes:

[97] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No subjects analyzed for this arm

| End point values | P1A 150mg | P1A 300mg | P1A 600mg | P1A 1200mg |
|-----------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 14 | 12 | 12 | 9 |
| Units: Participants | | | | |
| BMS-986179 ADA+ | 5 | 4 | 8 | 3 |
| Nivolumab ADA+ | 0 | 1 | 0 | 0 |

| End point values | P1A 1600mg | P1B Combo Therapy 150mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 360mg | P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg |
|-----------------------------|-----------------|-------------------------|--------------------------------------------------|--------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 12 | 9 | 8 | 7 |

| | | | | |
|---------------------|---|---|---|---|
| Units: Participants | | | | |
| BMS-986179 ADA+ | 2 | 5 | 6 | 5 |
| Nivolumab ADA+ | 0 | 1 | 1 | 0 |

| End point values | P1B BMS986-179 1600mg | P2 Combo Pancreatic | P2 Combo Therapy NSCLC | P2 Combo Melanoma |
|-----------------------------|-----------------------|---------------------|------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 18 | 19 | 31 | 15 |
| Units: Participants | | | | |
| BMS-986179 ADA+ | 11 | 9 | 22 | 9 |
| Nivolumab ADA+ | 0 | 2 | 0 | 0 |

| End point values | P2 Combo SCCHN | P2 Combo Prostate | P2 Combo Unassigned | P2 Monotherapy Unassigned |
|-----------------------------|-----------------|-------------------|---------------------|---------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 14 | 2 | 1 |
| Units: Participants | | | | |
| BMS-986179 ADA+ | 6 | 8 | 1 | 0 |
| Nivolumab ADA+ | 0 | 0 | 0 | 0 |

| End point values | P2 RCC Combo | P2 Combo RCC Crossover | | |
|-----------------------------|----------------------|------------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 18 | 3 | | |
| Units: Participants | | | | |
| BMS-986179 ADA+ | 14 | 2 | | |
| Nivolumab ADA+ | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Part 1 up to 25.1 months, Part 2 SC up to 17.5 months, RCC Mono up to 28.1 months, Part 2 up to 27.2 months.

All-cause mortality will be measured from randomization to study completion: approximately up to 5 years and 4 months

Adverse event reporting additional description:

Serious adverse events and other adverse events will be measured from first dose to 100 days post last dose:

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 24.1 |

Reporting groups

| | |
|-----------------------------------------------------------------------------|--------------------|
| Reporting group title | P1A BMS1200 |
| Reporting group description: BMS-986179 1200mg monotherapy | |
| Reporting group title | P1A BMS150 |
| Reporting group description: BMS-986179 150mg monotherapy | |
| Reporting group title | P1A BMS300 |
| Reporting group description: BMS-986179 300mg monotherapy | |
| Reporting group title | P1A BMS600 |
| Reporting group description: BMS-986179 600mg monotherapy | |
| Reporting group title | P1A BMS600+NIV240 |
| Reporting group description: BMS-986179 600mg + Nivo 240mg | |
| Reporting group title | P1A BMS300+NIV240 |
| Reporting group description: BMS-986179 300mg + Nivo 240mg | |
| Reporting group title | P1A BMS150+NIV240 |
| Reporting group description: BMS-986179 150mg + Nivo 240mg | |
| Reporting group title | P1A ALL MONO |
| Reporting group description: P1A all treated participants in monotherapy | |
| Reporting group title | P1A BMS1200+NIV240 |
| Reporting group description: BMS-986179 1200mg + Nivo 240mg | |
| Reporting group title | P1A BMS1600 |
| Reporting group description: BMS-986179 1600mg monotherapy | |
| Reporting group title | P1B BMS1200+NIV360 |
| Reporting group description: BMS-986179 1200mg + Nivo360mg | |
| Reporting group title | P1B BMS150+NIV360 |

Reporting group description:

BMS-986179 150mg + Nivo 360mg

| | |
|-----------------------|---------------|
| Reporting group title | P1A ALL COMBO |
|-----------------------|---------------|

Reporting group description:

P1A all treated participants in combo therapy

| | |
|-----------------------|--------------------|
| Reporting group title | P1A BMS1600+NIV240 |
|-----------------------|--------------------|

Reporting group description:

BMS-986179 1600mg + Nivo 240mg

| | |
|-----------------------|--------------------|
| Reporting group title | P1B BMS1200+NIV480 |
|-----------------------|--------------------|

Reporting group description:

BMS-986179 1200mg + Nivo 480mg

| | |
|-----------------------|---------------|
| Reporting group title | P1B BMS1600SC |
|-----------------------|---------------|

Reporting group description:

BMS-986179 1600mg SC

| | |
|-----------------------|---------------|
| Reporting group title | P1B ALL COMBO |
|-----------------------|---------------|

Reporting group description:

All treated participants in P1B combo therapy period

| | |
|-----------------------|---------------------|
| Reporting group title | P2 PANCREATIC COMBO |
|-----------------------|---------------------|

Reporting group description:

BMS-986179 1200mg Q2W + Nivo 240mg Q2W

| | |
|-----------------------|----------------|
| Reporting group title | P2 NSCLC COMBO |
|-----------------------|----------------|

Reporting group description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W

| | |
|-----------------------|-------------------|
| Reporting group title | P2 MELANOMA COMBO |
|-----------------------|-------------------|

Reporting group description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W

| | |
|-----------------------|------------------|
| Reporting group title | P2 2 SCCHN COMBO |
|-----------------------|------------------|

Reporting group description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W

| | |
|-----------------------|--------------|
| Reporting group title | P2 RCC COMBO |
|-----------------------|--------------|

Reporting group description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W

| | |
|-----------------------|-------------|
| Reporting group title | P2 RCC MONO |
|-----------------------|-------------|

Reporting group description:

BMS-986179 600mg Q2W Monotherapy

| | |
|-----------------------|------------------|
| Reporting group title | P2 RCC CROSSOVER |
|-----------------------|------------------|

Reporting group description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W

| | |
|-----------------------|-------------------|
| Reporting group title | P2 PROSTATE COMBO |
|-----------------------|-------------------|

Reporting group description:

BMS-986179 600mg Q2W + Nivo 480mg Q4W

| | |
|-----------------------|----------------------|
| Reporting group title | P2 NOT ASSIGNED MONO |
|-----------------------|----------------------|

Reporting group description:

BMS-986179 600mg Q2W

| | |
|-----------------------|-----------------------|
| Reporting group title | P2 NOT ASSIGNED COMBO |
|-----------------------|-----------------------|

Reporting group description:

BMS-986179 1200mg Q2W + Nivo 480mg Q4W

| | |
|-----------------------|--------------|
| Reporting group title | P2 ALL COMBO |
|-----------------------|--------------|

Reporting group description:

All Treated participants in the P2 treatment period

| | |
|-----------------------|------------------------|
| Reporting group title | ALL COMBO (P1A+P1B+P2) |
|-----------------------|------------------------|

| Serious adverse events | P1A BMS1200 | P1A BMS150 | P1A BMS300 |
|---------------------------------------------------------------------|--------------------|-------------------|-------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 3 / 14 (21.43%) | 4 / 12 (33.33%) |
| number of deaths (all causes) | 2 | 2 | 1 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm progression | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour associated fever | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |

| | | | |
|------------------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction gastric | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 14 (7.14%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion site infection | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis infective | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular device infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | P1A BMS600 | P1A BMS600+NIV240 | P1A BMS300+NIV240 |
|---------------------------------------------------|----------------|-------------------|-------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 9 / 12 (75.00%) | 6 / 11 (54.55%) |
| number of deaths (all causes) | 0 | 11 | 11 |
| number of deaths resulting from adverse events | | | |

| | | | |
|---------------------------------------------------------------------|----------------|-----------------|-----------------|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 4 / 12 (33.33%) | 4 / 11 (36.36%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm progression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour associated fever | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|------------------------------------------------------|----------------|----------------|----------------|
| General disorders and administration site conditions | | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction gastric | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated hepatitis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone pain | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion site infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis infective | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular device infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | P1A BMS150+NIV240 | P1A ALL MONO | P1A BMS1200+NIV240 |
|---------------------------------------------------------------------|----------------------|------------------|-----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 5 / 12 (41.67%) | 13 / 59 (22.03%) | 3 / 7 (42.86%) |
| number of deaths (all causes) | 9 | 7 | 6 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |

| | | | |
|------------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 4 / 59 (6.78%) | 2 / 7 (28.57%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm progression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour associated fever | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction gastric | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated hepatitis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 59 (5.08%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone pain | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion site infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis infective | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular device infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | P1A BMS1600 | P1B BMS1200+NIV360 | P1B BMS150+NIV360 |
|---------------------------------------------------------------------|-----------------|-----------------------|----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 7 / 8 (87.50%) | 7 / 9 (77.78%) |
| number of deaths (all causes) | 2 | 8 | 9 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |

| | | | |
|------------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 4 / 8 (50.00%) | 3 / 9 (33.33%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm progression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour associated fever | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction gastric | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated hepatitis | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone pain | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion site infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis infective | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular device infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | P1A ALL COMBO | P1A BMS1600+NIV240 | P1B BMS1200+NIV480 |
|---------------------------------------------------------------------|------------------|-----------------------|-----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 28 / 52 (53.85%) | 5 / 10 (50.00%) | 4 / 7 (57.14%) |
| number of deaths (all causes) | 45 | 8 | 5 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |

| | | | |
|------------------------------------------------------|------------------|-----------------|----------------|
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 13 / 52 (25.00%) | 2 / 10 (20.00%) | 2 / 7 (28.57%) |
| occurrences causally related to treatment / all | 0 / 13 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm progression | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour associated fever | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|-------------------------------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |

| | | | |
|-------------------------------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|-----------------|---------------|
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal fracture | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |

| | | | |
|-------------------------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 2 / 10 (20.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction gastric | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated hepatitis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone pain | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion site infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis infective | | | |

| | | | |
|-------------------------------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular device infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | P1B BMS1600SC | P1B ALL COMBO | P2 PANCREATIC COMBO |
|---------------------------------------------------------------------|------------------|------------------|---------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 11 / 18 (61.11%) | 18 / 24 (75.00%) | 8 / 19 (42.11%) |
| number of deaths (all causes) | 18 | 22 | 14 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |

| | | | |
|------------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 24 (8.33%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 9 / 24 (37.50%) | 8 / 19 (42.11%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 9 | 0 / 8 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm progression | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour associated fever | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 24 (8.33%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction gastric | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated hepatitis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone pain | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 2 / 19 (10.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary tract infection | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion site infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis infective | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular device infection | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | P2 NSCLC COMBO | P2 MELANOMA COMBO | P2 2 SCCHN COMBO |
|---------------------------------------------------------------------|------------------|-------------------|------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 14 / 31 (45.16%) | 8 / 15 (53.33%) | 11 / 15 (73.33%) |
| number of deaths (all causes) | 23 | 14 | 13 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |

| | | | |
|------------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 6 / 15 (40.00%) | 5 / 15 (33.33%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 6 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm progression | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour associated fever | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |

| | | | |
|-------------------------------------------------|-----------------|----------------|----------------|
| General physical health deterioration | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 4 / 31 (12.90%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 2 / 15 (13.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction gastric | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated hepatitis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone pain | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion site infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis infective | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular device infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | P2 RCC COMBO | P2 RCC MONO | P2 RCC CROSSOVER |
|---------------------------------------------------------------------|------------------|-----------------|------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 11 / 18 (61.11%) | 5 / 19 (26.32%) | 1 / 3 (33.33%) |
| number of deaths (all causes) | 9 | 8 | 1 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |

| | | | |
|------------------------------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 2 / 19 (10.53%) | 1 / 3 (33.33%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm progression | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour associated fever | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hemiparesis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction gastric | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated hepatitis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone pain | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion site infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis infective | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular device infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | P2 PROSTATE COMBO | P2 NOT ASSIGNED MONO | P2 NOT ASSIGNED COMBO |
|---------------------------------------------------------------------|-------------------|----------------------|-----------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 4 / 14 (28.57%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| number of deaths (all causes) | 13 | 0 | 1 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |

| | | | |
|------------------------------------------------------|-----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasm progression | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour associated fever | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hemiparesis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obstruction gastric | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subileus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated hepatitis | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone pain | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion site infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericarditis infective | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal cord infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular device infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | P2 ALL COMBO | ALL COMBO (P1A+P1B+P2) | |
|---------------------------------------------------------------------|-------------------|---------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 57 / 117 (48.72%) | 103 / 193 (53.37%) | |
| number of deaths (all causes) | 88 | 155 | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |

| | | | |
|------------------------------------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 3 / 193 (1.55%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 27 / 117 (23.08%) | 49 / 193 (25.39%) | |
| occurrences causally related to treatment / all | 0 / 27 | 0 / 49 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neoplasm | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neoplasm malignant | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neoplasm progression | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tumour associated fever | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tumour pain | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Haemorrhage | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| General physical health deterioration | | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 4 / 193 (2.07%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pain | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Performance status decreased | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 4 / 193 (2.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 6 / 117 (5.13%) | 8 / 193 (4.15%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngeal necrosis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonitis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Delirium | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Product issues | | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Weight decreased | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| Injury, poisoning and procedural complications | | | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvic fracture | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal fracture | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericardial effusion | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Carotid artery dissection | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Headache | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hemiparesis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sciatica | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal cord compression | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemolysis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ascites | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ileus | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal ischaemia | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 3 / 193 (1.55%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intra-abdominal haemorrhage | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nausea | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Obstruction gastric | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subileus | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vomiting | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Biliary obstruction | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune-mediated hepatitis | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hydronephrosis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 6 / 193 (3.11%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bone pain | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacteraemia | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Biliary tract infection | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infection | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infusion site infection | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericarditis infective | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Perinephric abscess | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 4 / 193 (2.07%) | |
| occurrences causally related to treatment / all | 1 / 3 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal cord infection | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urosepsis | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular device infection | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | P1A BMS1200 | P1A BMS150 | P1A BMS300 |
|---------------------------------------------------------------------|----------------|------------------|-----------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 6 / 9 (66.67%) | 11 / 14 (78.57%) | 8 / 12 (66.67%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Infected neoplasm | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Neoplasm malignant subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Tumour pain subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Vascular disorders | | | |
| Deep vein thrombosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Embolism subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Flushing subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 14 (7.14%) 1 | 0 / 12 (0.00%) 0 |
| Haematoma subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Haemorrhage subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Hot flush subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Hypotension subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Inferior vena cava stenosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Lymphoedema | | | |

| | | | |
|------------------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Face oedema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Inflammation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |

| | | | |
|------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 2 / 12 (16.67%) |
| occurrences (all) | 0 | 0 | 2 |
| Infusion site joint swelling | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xerosis | | | |

| | | | |
|--------------------------------------------------|--------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Immune system disorders | | | |
| Contrast media allergy | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Balanoposthitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Intermenstrual bleeding | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Testis discomfort | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal discharge | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleuritic pain | | | |

| | | | |
|--------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| Confusional state | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Depression | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ammonia increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Amylase decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Amylase increased | | | |

| | | | |
|-------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 2 | 0 | 1 |
| Blood alkaline phosphatase decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase MB increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |

| | | | |
|---------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood triglycerides abnormal | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood triglycerides increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urine present | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Electrocardiogram T wave inversion | | | |

| | | | |
|------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoglobin increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immature granulocyte count increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |

| | | | |
|---------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell sedimentation rate decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------------------------------------------------------------|--------------------|---------------------|---------------------|
| Red blood cells urine positive subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| SARS-CoV-2 test positive subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Transaminases increased subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Tri-iodothyronine free decreased subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Troponin I increased subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Urine leukocyte esterase positive subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Weight decreased subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Weight increased subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| White blood cells urine positive subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Fall | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Incision site pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Post procedural pruritus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural nausea | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural site reaction | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stoma site pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site rash | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound | | | |

| | | | |
|--------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound dehiscence | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Congenital, familial and genetic disorders | | | |
| Hydrocele | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac failure | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mitral valve disease | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinoatrial block | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sinus tachycardia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Amnesia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Central nervous system mass | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 2 | 0 | 1 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------|----------------|----------------|----------------|
| Memory impairment | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ophthalmic migraine | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Tremor subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia subjects affected / exposed occurrences (all) | 2 / 9 (22.22%) 2 | 1 / 14 (7.14%) 1 | 3 / 12 (25.00%) 3 |
| Eosinophilia subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Hyperleukocytosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Iron deficiency anaemia subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Leukocytosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Lymphopenia subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Splenic vein thrombosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Thrombocytosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Ear and labyrinth disorders | | | |
| Ear pain subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Middle ear effusion subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Middle ear inflammation | | | |

| | | | |
|--------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Tinnitus subjects affected / exposed occurrences (all) | 1 / 9 (11.11%) 1 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Vertigo subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Vestibular disorder subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Eye disorders Amaurosis subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Conjunctival haemorrhage subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Conjunctival oedema subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Diplopia subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Dry eye subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 1 / 14 (7.14%) 1 | 0 / 12 (0.00%) 0 |
| Eye disorder subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Eye irritation subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Eye oedema subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid oedema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xerophthalmia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 2 / 12 (16.67%) |
| occurrences (all) | 2 | 0 | 2 |
| Abdominal pain lower | | | |

| | | | |
|-----------------------------|---------------|----------------|-----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal erythema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal pruritus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 2 / 12 (16.67%) |
| occurrences (all) | 0 | 0 | 2 |
| Dental caries | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |

| | | | |
|----------------------------------|---------------|----------------|-----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 4 / 12 (33.33%) |
| occurrences (all) | 0 | 1 | 5 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal hypermotility | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |

| | | | |
|------------------------------|---------------|----------------|-----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip blister | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 2 / 12 (16.67%) |
| occurrences (all) | 0 | 0 | 2 |
| Odynophagia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral lichen planus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Small intestinal haemorrhage | | | |

| | | | |
|--------------------------------------------------|--------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Stomatitis | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Toothache | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Vomiting | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 4 / 12 (33.33%) 6 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Cholestasis | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Hepatic cytolysis | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Hypertransaminaemia | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Jaundice | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed occurrences (all) | 0 / 9 (0.00%) 0 | 0 / 14 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |

| | | | |
|---------------------------------------------|---------------|-----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 2 / 14 (14.29%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fragility | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hypopigmentation | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| Skin induration | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vitiligo | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xeroderma | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chromaturia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |

| | | | |
|----------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocyturia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Strangury | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inappropriate antidiuretic hormone secretion | | | |

| | | | |
|----------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 2 / 9 (22.22%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Clubbing | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint stiffness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myopathy | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |

| | | | |
|-----------------------------|---------------|-----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 2 / 14 (14.29%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Sarcopenia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Trismus | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| Herpes virus infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal herpes | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------------|---------------|----------------|----------------|
| Oral herpes | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periodontitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Propionibacterium infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------------|----------------|----------------|-----------------|
| Sepsis | | | |
| subjects affected / exposed | 1 / 9 (11.11%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 2 / 12 (16.67%) |
| occurrences (all) | 0 | 0 | 2 |
| Dehydration | | | |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 1 / 14 (7.14%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypomagnesaemia | | | |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Iron deficiency | | | |
| subjects affected / exposed | 0 / 9 (0.00%) | 0 / 14 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | P1A BMS600 | P1A BMS600+NIV240 | P1A BMS300+NIV240 |
|---------------------------------------------------------------------|-----------------|----------------------|----------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 8 / 12 (66.67%) | 12 / 12 (100.00%) | 11 / 11 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Infected neoplasm | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 2 / 11 (18.18%) |
| occurrences (all) | 0 | 0 | 2 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Embolism | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flushing | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematoma | | | |

| | | | |
|--------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 1 | 0 | 1 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Inferior vena cava stenosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Face oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |

| | | | |
|------------------------------|----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 4 / 12 (33.33%) | 4 / 11 (36.36%) |
| occurrences (all) | 0 | 4 | 5 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 12 (16.67%) | 1 / 11 (9.09%) |
| occurrences (all) | 1 | 2 | 2 |
| Infusion site joint swelling | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |

| | | | |
|------------------------------------------|----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 1 | 1 |
| Oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 12 (25.00%) | 5 / 11 (45.45%) |
| occurrences (all) | 0 | 3 | 5 |
| Pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 1 | 1 |
| Xerosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Contrast media allergy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Balanoposthitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Intermenstrual bleeding | | | |

| | | | |
|-------------------------------------------------|----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Testis discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal discharge | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 3 / 12 (25.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 1 | 5 | 1 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 12 (16.67%) | 3 / 11 (27.27%) |
| occurrences (all) | 1 | 2 | 3 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |

| | | | |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 1 | 1 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |

| | | | |
|--------------------------------------|----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 12 (25.00%) | 2 / 11 (18.18%) |
| occurrences (all) | 0 | 3 | 2 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|--------------------------------------------------------------------------------------------------------------------------|---------------------|----------------------|---------------------|
| Sleep disorder subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Product issues Device dislocation subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Investigations Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 11 (0.00%) 0 |
| Ammonia increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Amylase decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Amylase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 2 / 12 (16.67%) 2 | 1 / 11 (9.09%) 3 |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 11 (0.00%) 0 |
| Blood alkaline phosphatase decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Blood alkaline phosphatase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 11 (0.00%) 0 |
| Blood bilirubin increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 2 | 0 / 11 (0.00%) 0 |

| | | | |
|---------------------------------------------|----------------|-----------------|----------------|
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase MB increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Blood creatine phosphokinase decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 12 (25.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 12 (16.67%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 3 | 2 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |

| | | | |
|--------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Blood triglycerides abnormal subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Blood triglycerides increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Blood urea increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Blood uric acid increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Blood urine present subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Electrocardiogram T wave inversion subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 11 (0.00%) 0 |
| Glomerular filtration rate decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Glycosylated haemoglobin increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Haemoglobin increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Heart rate decreased | | | |

| | | | |
|------------------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immature granulocyte count increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lipase decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 12 (16.67%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 5 | 4 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |

| | | | |
|---------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell sedimentation rate decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cells urine positive | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tri-iodothyronine free decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Troponin I increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Urine leukocyte esterase positive subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Weight decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 1 / 11 (9.09%) 1 |
| Weight increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 2 | 0 / 11 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| White blood cells urine positive subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 3 | 0 / 11 (0.00%) 0 |
| Fall subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Incision site pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Infusion related reaction subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 1 / 11 (9.09%) 1 |
| Post procedural pruritus subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Procedural nausea subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Procedural pain | | | |

| | | | |
|--------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Procedural site reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Stoma site pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site rash | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Wound | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound dehiscence | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Congenital, familial and genetic disorders | | | |
| Hydrocele | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac failure | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mitral valve disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinoatrial block | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus tachycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Central nervous system mass | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|-------------------------------|-----------------|-----------------|----------------|
| Dizziness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 12 (16.67%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Ophthalmic migraine | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|--------------------------------------|----------------|----------------|-----------------|
| Presyncope | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 3 / 11 (27.27%) |
| occurrences (all) | 0 | 0 | 6 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperleukocytosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vestibular disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Amaurosis | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Conjunctival oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Eye disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 2 |
| Eye oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 1 | 1 |
| Eyelid oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Periorbital oedema | | | |

| | | | |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 2 | 1 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xerophthalmia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 3 / 12 (25.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal erythema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| Anal pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 12 (16.67%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 3 / 12 (25.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 2 | 4 | 1 |
| Dental caries | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 12 (16.67%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 3 | 1 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------|----------------|----------------|----------------|
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal hypermotility | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lip blister | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------|-----------------|-----------------|-----------------|
| Nausea | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 0 / 12 (0.00%) | 7 / 11 (63.64%) |
| occurrences (all) | 4 | 0 | 8 |
| Odynophagia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral lichen planus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 2 / 12 (16.67%) | 5 / 11 (45.45%) |
| occurrences (all) | 3 | 2 | 6 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |

| | | | |
|----------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------------------|----------------|----------------|-----------------|
| Dry skin | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 2 / 11 (18.18%) |
| occurrences (all) | 0 | 1 | 2 |
| Rash | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin fragility | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hypopigmentation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Vitiligo | | | |

| | | | |
|----------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Xeroderma subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Renal and urinary disorders | | | |
| Bladder spasm subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Chromaturia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Chronic kidney disease subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Dysuria subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 1 / 12 (8.33%) 1 | 0 / 11 (0.00%) 0 |
| Haematuria subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Hydronephrosis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Leukocyturia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Nocturia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 11 (0.00%) 0 |
| Pollakiuria subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Proteinuria subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |

| | | | |
|-------------------------------------------------|----------------|-----------------|-----------------|
| Strangury | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 2 / 11 (18.18%) |
| occurrences (all) | 0 | 0 | 2 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 2 / 11 (18.18%) |
| occurrences (all) | 0 | 1 | 3 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Back pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 12 (16.67%) | 0 / 11 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |

| | | | |
|---------------------------------|----------------|-----------------|----------------|
| Bone pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Clubbing | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Joint stiffness | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 12 (16.67%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 3 / 12 (25.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |

| | | | |
|------------------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Musculoskeletal discomfort subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Musculoskeletal pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Musculoskeletal stiffness subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 11 (0.00%) 0 |
| Myalgia subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 2 / 11 (18.18%) 2 |
| Myopathy subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Neck pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Osteoarthritis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 1 / 11 (9.09%) 1 |
| Sarcopenia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Trismus subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Infections and infestations Bacteraemia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 11 (0.00%) 0 |
| Bronchitis | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Herpes virus infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised infection | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal herpes | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oral infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Periodontitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |

| | | | |
|-----------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Propionibacterium infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |

| | | | |
|------------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound infection | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 12 (16.67%) | 1 / 11 (9.09%) |
| occurrences (all) | 1 | 2 | 1 |
| Dehydration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 11 (9.09%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 2 / 11 (18.18%) |
| occurrences (all) | 0 | 0 | 2 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 11 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | P1A BMS150+NIV240 | P1A ALL MONO | P1A BMS1200+NIV240 |
|---------------------------------------------------------------------|----------------------|------------------|-----------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 11 / 12 (91.67%) | 45 / 59 (76.27%) | 7 / 7 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|--------------------------------------------------------------------------|---------------------|---------------------|--------------------|
| Infected neoplasm subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 59 (1.69%) 1 | 0 / 7 (0.00%) 0 |
| Neoplasm malignant subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tumour pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 59 (1.69%) 1 | 0 / 7 (0.00%) 0 |
| Vascular disorders | | | |
| Deep vein thrombosis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Embolism subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Flushing subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 59 (1.69%) 1 | 0 / 7 (0.00%) 0 |
| Haematoma subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Haemorrhage subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hot flush subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 59 (1.69%) 1 | 0 / 7 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 59 (1.69%) 1 | 0 / 7 (0.00%) 0 |
| Hypotension subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 59 (1.69%) 1 | 0 / 7 (0.00%) 0 |
| Inferior vena cava stenosis | | | |

| | | | |
|------------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 4 / 59 (6.78%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 4 | 3 |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Chest pain | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Face oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Fatigue | | | |
| subjects affected / exposed | 4 / 12 (33.33%) | 3 / 59 (5.08%) | 2 / 7 (28.57%) |
| occurrences (all) | 4 | 3 | 2 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 2 |
| Inflammation | | | |

| | | | |
|------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 3 / 59 (5.08%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Infusion site joint swelling | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 3 / 59 (5.08%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Oedema | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 1 / 59 (1.69%) | 5 / 7 (71.43%) |
| occurrences (all) | 3 | 1 | 5 |
| Pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pyrexia | | | |

| | | | |
|-----------------------------------------------------------------------------------------------------------------|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 5 / 12 (41.67%) 6 | 1 / 59 (1.69%) 1 | 2 / 7 (28.57%) 3 |
| Xerosis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Immune system disorders Contrast media allergy subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Seasonal allergy subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Reproductive system and breast disorders Balanoposthitis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Intermenstrual bleeding subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 59 (1.69%) 1 | 0 / 7 (0.00%) 0 |
| Pelvic pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Testis discomfort subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Vaginal discharge subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Vaginal haemorrhage subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| Asthma | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 4 / 12 (33.33%) | 3 / 59 (5.08%) | 1 / 7 (14.29%) |
| occurrences (all) | 4 | 3 | 1 |
| Dysphonia | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 4 / 59 (6.78%) | 2 / 7 (28.57%) |
| occurrences (all) | 2 | 4 | 2 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |

| | | | |
|--------------------------------------|----------------|----------------|----------------|
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-------------------------------------------------|-----------------|----------------|----------------|
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 59 (3.39%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 1 | 1 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 1 | 1 |
| Ammonia increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------|----------------|----------------|----------------|
| Amylase decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Amylase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 3 / 59 (5.08%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Blood alkaline phosphatase decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase MB increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blood glucose decreased | | | |

| | | | |
|---------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood triglycerides abnormal | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood triglycerides increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urine present | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |

| | | | |
|------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Electrocardiogram T wave inversion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoglobin increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Immature granulocyte count increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase decreased | | | |

| | | | |
|-----------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell sedimentation rate | | | |

| | | | |
|------------------------------------------------|-----------------|----------------|----------------|
| decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cells urine positive | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tri-iodothyronine free decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Troponin I increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine leukocyte esterase positive | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| White blood cell count increased | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| White blood cells urine positive | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| Contusion | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Incision site pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 59 (5.08%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Post procedural pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural nausea | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural site reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stoma site pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------------------------------------------------------------------|---------------------|---------------------|--------------------|
| Vascular access site rash subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Wound subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Wound dehiscence subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Congenital, familial and genetic disorders Hydrocele subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cardiac disorders Atrial fibrillation subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cardiac failure subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Mitral valve disease subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinoatrial block subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinus bradycardia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 59 (1.69%) 1 | 0 / 7 (0.00%) 0 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tachycardia | | | |

| | | | |
|--------------------------------------------------|---------------------|---------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 59 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Central nervous system mass | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 9 / 59 (15.25%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 9 | 2 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------|----------------|----------------|----------------|
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ophthalmic migraine | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------|-----------------|-----------------|----------------|
| Taste disorder | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 9 / 59 (15.25%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 9 | 0 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperleukocytosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear effusion | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vestibular disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Amaurosis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Eye disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| Eye oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Eyelid oedema | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Xerophthalmia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 2 / 59 (3.39%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Abdominal pain | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 5 / 59 (8.47%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 6 | 4 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 1 | 1 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal erythema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 4 / 59 (6.78%) | 2 / 7 (28.57%) |
| occurrences (all) | 3 | 4 | 2 |
| Dental caries | | | |

| | | | |
|----------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 6 / 12 (50.00%) | 6 / 59 (10.17%) | 3 / 7 (42.86%) |
| occurrences (all) | 6 | 7 | 4 |
| Dry mouth | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 0 | 1 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal hypermotility | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Glossitis | | | |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip blister | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 4 / 12 (33.33%) | 6 / 59 (10.17%) | 1 / 7 (14.29%) |
| occurrences (all) | 4 | 7 | 1 |
| Odynophagia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral lichen planus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |

| | | | |
|------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Vomiting | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 6 / 59 (10.17%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 9 | 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------------|-----------------|----------------|----------------|
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 1 | 1 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 59 (3.39%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |

| | | | |
|---------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 59 (3.39%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 2 | 1 |
| Rash | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 2 / 7 (28.57%) |
| occurrences (all) | 1 | 1 | 3 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fragility | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| Skin hypopigmentation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Vitiligo | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xeroderma | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chromaturia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haematuria | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocyturia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Strangury | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|-------------------------------------------------|-----------------|----------------|----------------|
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 3 / 59 (5.08%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 3 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 1 | 1 |
| Bone pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Clubbing | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint stiffness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Joint swelling | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 59 (3.39%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Myopathy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 2 |
| Osteoarthritis | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 59 (3.39%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 2 | 1 |
| Sarcopenia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Trismus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Herpes virus infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal herpes | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------------|----------------|----------------|---------------|
| Oral herpes | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periodontitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Propionibacterium infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------------|-----------------|----------------|----------------|
| Sepsis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Urinary tract infection | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 6 / 12 (50.00%) | 3 / 59 (5.08%) | 0 / 7 (0.00%) |
| occurrences (all) | 6 | 3 | 0 |
| Dehydration | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 1 | 1 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 1 | 1 |
| Hypomagnesaemia | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 1 | 1 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 59 (1.69%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 59 (3.39%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 59 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| Non-serious adverse events | P1A BMS1600 | P1B BMS1200+NIV360 | P1B BMS150+NIV360 |
|---------------------------------------------------------------------|-------------------|-----------------------|----------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 12 / 12 (100.00%) | 6 / 8 (75.00%) | 9 / 9 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Infected neoplasm | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Embolism | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flushing | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematoma | | | |

| | | | |
|--------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inferior vena cava stenosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 2 / 12 (16.67%) | 2 / 8 (25.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 2 | 2 | 2 |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Face oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |

| | | | |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 8 (12.50%) | 4 / 9 (44.44%) |
| occurrences (all) | 1 | 1 | 4 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Infusion site joint swelling | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |

| | | | |
|------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 2 / 12 (16.67%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 8 (37.50%) | 2 / 9 (22.22%) |
| occurrences (all) | 0 | 4 | 2 |
| Pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Xerosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Contrast media allergy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Balanoposthitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Intermenstrual bleeding | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Testis discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal discharge | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 8 (25.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 2 | 1 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |

| | | | |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |

| | | | |
|--------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------------------------------------------------------------------------------------------|---------------------|--------------------|---------------------|
| Sleep disorder subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Product issues Device dislocation subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Investigations Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Ammonia increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Amylase decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Amylase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Blood alkaline phosphatase decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Blood alkaline phosphatase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Blood bilirubin increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |

| | | | |
|---------------------------------------------|----------------|---------------|---------------|
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase MB increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------------------------------------------------------------|---------------------|--------------------|--------------------|
| Blood triglycerides abnormal subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Blood triglycerides increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Blood urea increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Blood uric acid increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Blood urine present subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Electrocardiogram T wave inversion subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Glomerular filtration rate decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Glycosylated haemoglobin increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Haemoglobin increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Heart rate decreased | | | |

| | | | |
|------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immature granulocyte count increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |

| | | | |
|---------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell sedimentation rate decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cells urine positive | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tri-iodothyronine free decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Troponin I increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------------------------------------------------------------|---------------------|--------------------|---------------------|
| Urine leukocyte esterase positive subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Weight decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Weight increased subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| White blood cells urine positive subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Fall subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Incision site pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Infusion related reaction subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Post procedural pruritus subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Procedural nausea subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Procedural pain | | | |

| | | | |
|-------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Procedural site reaction subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Rib fracture subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Skin abrasion subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Stoma site pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Vascular access site pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 8 (12.50%) 1 | 0 / 9 (0.00%) 0 |
| Vascular access site rash subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Wound subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Wound dehiscence subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Congenital, familial and genetic disorders Hydrocele subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Cardiac disorders Atrial fibrillation subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Cardiac failure | | | |

| | | | |
|-----------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mitral valve disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinoatrial block | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus tachycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Central nervous system mass | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------|-----------------|----------------|----------------|
| Dizziness | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 3 | 0 | 2 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Loss of consciousness | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ophthalmic migraine | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------|-----------------|----------------|----------------|
| Presyncope | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Taste disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 3 / 12 (25.00%) | 3 / 8 (37.50%) | 1 / 9 (11.11%) |
| occurrences (all) | 3 | 3 | 1 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperleukocytosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear effusion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear inflammation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vestibular disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Amaurosis | | | |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Periorbital oedema | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xerophthalmia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 0 | 1 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 8 (25.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 1 | 2 | 3 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Anal erythema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Anal pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 3 / 9 (33.33%) |
| occurrences (all) | 0 | 1 | 3 |
| Dental caries | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 8 (12.50%) | 2 / 9 (22.22%) |
| occurrences (all) | 1 | 1 | 4 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 3 / 9 (33.33%) |
| occurrences (all) | 0 | 0 | 3 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Dysphagia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------|----------------|---------------|----------------|
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal hypermotility | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Lip blister | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------|----------------|----------------|----------------|
| Nausea | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 8 (12.50%) | 3 / 9 (33.33%) |
| occurrences (all) | 1 | 2 | 5 |
| Odynophagia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral lichen planus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 0 | 0 | 5 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |

| | | | |
|----------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------------|----------------|---------------|----------------|
| Dry skin | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palmar-plantar erythrodysesthesia syndrome | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 3 / 9 (33.33%) |
| occurrences (all) | 0 | 0 | 3 |
| Rash | | | |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash pruritic | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fragility | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hypopigmentation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitiligo | | | |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xeroderma | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chromaturia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocyturia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| Strangury | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 1 | 1 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 8 (25.00%) | 3 / 9 (33.33%) |
| occurrences (all) | 0 | 2 | 4 |

| | | | |
|---------------------------------|----------------|----------------|---------------|
| Bone pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Clubbing | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint stiffness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|------------------------------------------------------------------------------------------------|---------------------|--------------------|---------------------|
| Musculoskeletal discomfort subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Musculoskeletal pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Musculoskeletal stiffness subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Myalgia subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 8 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Myopathy subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Neck pain subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Osteoarthritis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Sarcopenia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Trismus subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 1 / 9 (11.11%) 1 |
| Infections and infestations Bacteraemia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 8 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Bronchitis | | | |

| | | | |
|-----------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes virus infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised infection | | | |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal herpes | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Periodontitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |

| | | | |
|-----------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Propionibacterium infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |

| | | | |
|------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 0 | 1 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 3 / 9 (33.33%) |
| occurrences (all) | 0 | 0 | 4 |
| Dehydration | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 1 / 9 (11.11%) |
| occurrences (all) | 0 | 1 | 1 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 8 (12.50%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 8 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 1 | 0 | 2 |
| Iron deficiency | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 8 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | P1A ALL COMBO | P1A BMS1600+NIV240 | P1B BMS1200+NIV480 |
|---------------------------------------------------------------------|------------------|-----------------------|-----------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 50 / 52 (96.15%) | 9 / 10 (90.00%) | 6 / 7 (85.71%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|--------------------------------------------------------------------------|---------------------|----------------------|--------------------|
| Infected neoplasm subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Neoplasm malignant subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tumour pain subjects affected / exposed occurrences (all) | 2 / 52 (3.85%) 2 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Vascular disorders | | | |
| Deep vein thrombosis subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Embolism subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Flushing subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Haematoma subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Haemorrhage subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hot flush subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 2 / 52 (3.85%) 2 | 1 / 10 (10.00%) 1 | 0 / 7 (0.00%) 0 |
| Hypotension subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Inferior vena cava stenosis | | | |

| | | | |
|------------------------------------------------------|-----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphoedema | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 6 / 52 (11.54%) | 3 / 10 (30.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 7 | 3 | 0 |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chest pain | | | |

| | | | |
|-----------------------------|------------------|----------------|----------------|
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Face oedema | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Facial pain | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 14 / 52 (26.92%) | 0 / 10 (0.00%) | 5 / 7 (71.43%) |
| occurrences (all) | 15 | 0 | 5 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Inflammation | | | |

| | | | |
|------------------------------|------------------|-----------------|---------------|
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Infusion site joint swelling | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Oedema | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 19 / 52 (36.54%) | 3 / 10 (30.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 19 | 3 | 0 |
| Pain | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 2 / 10 (20.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pyrexia | | | |

| | | | |
|-----------------------------------------------------------------------------------------------------------------|------------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 10 / 52 (19.23%) 12 | 1 / 10 (10.00%) 1 | 2 / 7 (28.57%) 2 |
| Xerosis subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Immune system disorders Contrast media allergy subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Seasonal allergy subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 1 / 10 (10.00%) 1 | 0 / 7 (0.00%) 0 |
| Reproductive system and breast disorders Balanoposthitis subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Intermenstrual bleeding subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Pelvic pain subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Testis discomfort subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Vaginal discharge subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 1 / 10 (10.00%) 1 | 0 / 7 (0.00%) 0 |
| Vaginal haemorrhage subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |

| | | | |
|-----------------------------|------------------|-----------------|----------------|
| Asthma | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 14 / 52 (26.92%) | 5 / 10 (50.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 16 | 5 | 2 |
| Dysphonia | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 12 / 52 (23.08%) | 3 / 10 (30.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 12 | 3 | 1 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 5 / 52 (9.62%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 5 | 1 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|--------------------------------------|----------------|-----------------|----------------|
| Pleural effusion | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Sinus congestion | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |

| | | | |
|-------------------------------------------------|-----------------|-----------------|----------------|
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 3 / 10 (30.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 4 | 3 | 1 |
| Confusional state | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 7 / 52 (13.46%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 7 | 0 | 1 |
| Restlessness | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Ammonia increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------|----------------|-----------------|----------------|
| Amylase decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Amylase increased | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 6 | 1 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood alkaline phosphatase decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase MB increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood creatine phosphokinase decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 6 | 0 | 1 |
| Blood glucose decreased | | | |

| | | | |
|---------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood triglycerides abnormal | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood triglycerides increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urine present | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |

| | | | |
|------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Electrocardiogram T wave inversion | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoglobin increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Immature granulocyte count increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lipase decreased | | | |

| | | | |
|-----------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 1 / 10 (10.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 10 | 1 | 1 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell sedimentation rate | | | |

| | | | |
|------------------------------------------------|----------------|----------------|----------------|
| decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cells urine positive | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tri-iodothyronine free decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Troponin I increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urine leukocyte esterase positive | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 0 / 10 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 4 | 0 | 2 |
| Weight increased | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| White blood cell count increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| White blood cells urine positive | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| Contusion | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Incision site pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Post procedural pruritus | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural nausea | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Procedural site reaction | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Stoma site pain | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Vascular access site pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------------------------------------------------------------------|---------------------|----------------------|--------------------|
| Vascular access site rash subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Wound subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 1 / 10 (10.00%) 1 | 0 / 7 (0.00%) 0 |
| Wound dehiscence subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Congenital, familial and genetic disorders Hydrocele subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cardiac disorders Atrial fibrillation subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Cardiac failure subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Mitral valve disease subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinoatrial block subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinus bradycardia subjects affected / exposed occurrences (all) | 0 / 52 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 0 / 10 (0.00%) 0 | 0 / 7 (0.00%) 0 |
| Tachycardia | | | |

| | | | |
|--------------------------------------------------|---------------------|----------------------|--------------------|
| subjects affected / exposed occurrences (all) | 1 / 52 (1.92%) 1 | 1 / 10 (10.00%) 1 | 0 / 7 (0.00%) 0 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Central nervous system mass | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Headache | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 1 / 10 (10.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 4 | 1 | 1 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-------------------------------|----------------|-----------------|----------------|
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 0 | 0 | 1 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 0 | 1 |
| Ophthalmic migraine | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Seizure | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------|-----------------|-----------------|----------------|
| Taste disorder | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 8 / 52 (15.38%) | 2 / 10 (20.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 11 | 2 | 1 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperleukocytosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear effusion | | | |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear inflammation | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vestibular disorder | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Amaurosis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Conjunctival oedema | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Eye disorder | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| Eye oedema | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Eyelid oedema | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Xerophthalmia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Abdominal pain | | | |

| | | | |
|-----------------------------|------------------|-----------------|----------------|
| subjects affected / exposed | 5 / 52 (9.62%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 8 | 0 | 2 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal erythema | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Anal haemorrhage | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal pruritus | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 11 / 52 (21.15%) | 2 / 10 (20.00%) | 3 / 7 (42.86%) |
| occurrences (all) | 12 | 2 | 3 |
| Dental caries | | | |

| | | | |
|----------------------------------|------------------|-----------------|----------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 14 / 52 (26.92%) | 2 / 10 (20.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 16 | 2 | 2 |
| Dry mouth | | | |
| subjects affected / exposed | 6 / 52 (11.54%) | 2 / 10 (20.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 7 | 3 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 1 | 0 | 1 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Gastrointestinal hypermotility | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Glossitis | | | |

| | | | |
|-----------------------------|------------------|-----------------|---------------|
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lip blister | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Nausea | | | |
| subjects affected / exposed | 13 / 52 (25.00%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 15 | 2 | 0 |
| Odynophagia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral lichen planus | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rectal haemorrhage | | | |

| | | | |
|------------------------------|------------------|-----------------|----------------|
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 12 / 52 (23.08%) | 3 / 10 (30.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 14 | 4 | 1 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cholestasis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Jaundice | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------------|----------------|-----------------|----------------|
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 1 | 1 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Onychoclasia | | | |

| | | | |
|---------------------------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 5 / 52 (9.62%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 5 | 1 | 0 |
| Rash | | | |
| subjects affected / exposed | 5 / 52 (9.62%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 7 | 2 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin fragility | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| Skin hypopigmentation | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Vitiligo | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xeroderma | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chromaturia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haematuria | | | |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocyturia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Strangury | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 5 / 52 (9.62%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 5 | 1 | 0 |

| | | | |
|-------------------------------------------------|-----------------|-----------------|----------------|
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 7 / 52 (13.46%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 9 | 2 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 8 / 52 (15.38%) | 4 / 10 (40.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 8 | 4 | 2 |
| Bone pain | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Clubbing | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Joint stiffness | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |

| | | | |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb discomfort | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 5 / 52 (9.62%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 5 | 1 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 1 | 1 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Myopathy | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Osteoarthritis | | | |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Sarcopenia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Trismus | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 2 / 10 (20.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| Herpes virus infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal herpes | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------------|----------------|-----------------|---------------|
| Oral herpes | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oral infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Periodontitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Propionibacterium infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |

| | | | |
|------------------------------------|------------------|-----------------|----------------|
| Sepsis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 3 / 52 (5.77%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 3 | 0 | 1 |
| Urinary tract infection | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 11 / 52 (21.15%) | 2 / 10 (20.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 11 | 2 | 0 |
| Dehydration | | | |

| | | | |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 2 / 7 (28.57%) |
| occurrences (all) | 2 | 0 | 2 |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 1 / 10 (10.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 1 | 1 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 1 / 10 (10.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 4 | 4 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 52 (0.00%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 4 / 52 (7.69%) | 2 / 10 (20.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 5 | 3 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypomagnesaemia | | | |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 6 / 52 (11.54%) | 2 / 10 (20.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 6 | 2 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 0 / 10 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 0 | 1 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 2 / 52 (3.85%) | 2 / 10 (20.00%) | 1 / 7 (14.29%) |
| occurrences (all) | 2 | 2 | 1 |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 52 (1.92%) | 0 / 10 (0.00%) | 0 / 7 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| Non-serious adverse events | P1B BMS1600SC | P1B ALL COMBO | P2 PANCREATIC COMBO |
|---------------------------------------------------------------------|------------------|------------------|---------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 17 / 18 (94.44%) | 21 / 24 (87.50%) | 17 / 19 (89.47%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Infected neoplasm | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 1 | 1 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Embolism | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Flushing | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematoma | | | |

| | | | |
|--------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 2 / 19 (10.53%) |
| occurrences (all) | 2 | 0 | 2 |
| Inferior vena cava stenosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombosis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| General disorders and administration | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 4 / 24 (16.67%) | 5 / 19 (26.32%) |
| occurrences (all) | 1 | 4 | 6 |
| Axillary pain | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Early satiety | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Face oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |

| | | | |
|------------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 9 / 18 (50.00%) | 10 / 24 (41.67%) | 6 / 19 (31.58%) |
| occurrences (all) | 9 | 10 | 6 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inflammation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Infusion site joint swelling | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Malaise | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |

| | | | |
|------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 2 | 0 | 1 |
| Oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Oedema peripheral | | | |
| subjects affected / exposed | 4 / 18 (22.22%) | 5 / 24 (20.83%) | 5 / 19 (26.32%) |
| occurrences (all) | 5 | 6 | 5 |
| Pain | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 2 / 19 (10.53%) |
| occurrences (all) | 1 | 0 | 2 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 6 / 18 (33.33%) | 2 / 24 (8.33%) | 4 / 19 (21.05%) |
| occurrences (all) | 7 | 2 | 4 |
| Xerosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Contrast media allergy | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Balanoposthitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Intermenstrual bleeding | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pelvic pain | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Testis discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal discharge | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 3 / 24 (12.50%) | 4 / 19 (21.05%) |
| occurrences (all) | 3 | 3 | 4 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 4 / 18 (22.22%) | 4 / 24 (16.67%) | 5 / 19 (26.32%) |
| occurrences (all) | 4 | 4 | 5 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hiccups | | | |

| | | | |
|------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |

| | | | |
|--------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 1 | 1 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 2 / 24 (8.33%) | 2 / 19 (10.53%) |
| occurrences (all) | 2 | 2 | 2 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Depression | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Sleep disorder subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Product issues Device dislocation subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Investigations Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 1 / 24 (4.17%) 1 | 3 / 19 (15.79%) 4 |
| Ammonia increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 24 (0.00%) 0 | 1 / 19 (5.26%) 1 |
| Amylase decreased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Amylase increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 2 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 1 / 24 (4.17%) 1 | 5 / 19 (26.32%) 6 |
| Blood alkaline phosphatase decreased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Blood alkaline phosphatase increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 24 (0.00%) 0 | 1 / 19 (5.26%) 1 |
| Blood bilirubin increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 3 / 19 (15.79%) 3 |

| | | | |
|---------------------------------------------|----------------|----------------|----------------|
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase MB increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Blood triglycerides abnormal subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Blood triglycerides increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Blood urea increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Blood uric acid increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Blood urine present subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Electrocardiogram T wave inversion subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Glomerular filtration rate decreased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Glycosylated haemoglobin increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Haemoglobin increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Heart rate decreased | | | |

| | | | |
|------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 7 |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 2 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immature granulocyte count increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 1 | 1 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 2 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |

| | | | |
|---------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell sedimentation rate decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cells urine positive | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tri-iodothyronine free decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Troponin I increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------------------------------------------------------------|---------------------|----------------------|----------------------|
| Urine leukocyte esterase positive subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Weight decreased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 3 / 24 (12.50%) 3 | 1 / 19 (5.26%) 1 |
| Weight increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| White blood cells urine positive subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Fall subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 1 / 19 (5.26%) 1 |
| Incision site pain subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Infusion related reaction subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 2 / 19 (10.53%) 2 |
| Post procedural pruritus subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 1 / 19 (5.26%) 1 |
| Procedural nausea subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Procedural pain | | | |

| | | | |
|--------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 0 | 1 |
| Procedural site reaction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stoma site pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vascular access site rash | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound dehiscence | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Congenital, familial and genetic disorders | | | |
| Hydrocele | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cardiac failure | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Mitral valve disease | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 0 | 1 |
| Sinoatrial block | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus tachycardia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Burning sensation | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Central nervous system mass | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------|----------------|----------------|----------------|
| Dizziness | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 24 (8.33%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 2 / 24 (8.33%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Ophthalmic migraine | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------|-----------------|-----------------|-----------------|
| Presyncope | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Tremor | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 5 / 24 (20.83%) | 2 / 19 (10.53%) |
| occurrences (all) | 2 | 5 | 2 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperleukocytosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear effusion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear inflammation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vestibular disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Amaurosis | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |

| | | | |
|--------------------------------------------------------------------------|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Vision blurred subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 1 / 24 (4.17%) 1 | 0 / 19 (0.00%) 0 |
| Visual impairment subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Xerophthalmia subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort subjects affected / exposed occurrences (all) | 2 / 18 (11.11%) 2 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Abdominal distension subjects affected / exposed occurrences (all) | 2 / 18 (11.11%) 2 | 1 / 24 (4.17%) 1 | 0 / 19 (0.00%) 0 |
| Abdominal pain subjects affected / exposed occurrences (all) | 7 / 18 (38.89%) 7 | 4 / 24 (16.67%) 7 | 4 / 19 (21.05%) 4 |
| Abdominal pain lower subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 1 / 19 (5.26%) 1 |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 3 / 19 (15.79%) 3 |
| Abdominal tenderness subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 1 / 24 (4.17%) 1 | 0 / 19 (0.00%) 0 |
| Anal erythema subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Anal haemorrhage subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| Anal pruritus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 1 / 24 (4.17%) | 7 / 19 (36.84%) |
| occurrences (all) | 2 | 1 | 7 |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 4 / 18 (22.22%) | 7 / 24 (29.17%) | 4 / 19 (21.05%) |
| occurrences (all) | 4 | 7 | 4 |
| Dental caries | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 4 / 24 (16.67%) | 1 / 19 (5.26%) |
| occurrences (all) | 2 | 7 | 2 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 3 / 24 (12.50%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 3 | 1 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 2 / 24 (8.33%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------|----------------|----------------|----------------|
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal hypermotility | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 1 | 1 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 1 | 1 |
| Lip blister | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melaena | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------|-----------------|-----------------|-----------------|
| Nausea | | | |
| subjects affected / exposed | 5 / 18 (27.78%) | 4 / 24 (16.67%) | 4 / 19 (21.05%) |
| occurrences (all) | 5 | 7 | 4 |
| Odynophagia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral lichen planus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 2 / 19 (10.53%) |
| occurrences (all) | 0 | 0 | 2 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 0 | 1 |
| Toothache | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 4 / 18 (22.22%) | 3 / 24 (12.50%) | 3 / 19 (15.79%) |
| occurrences (all) | 4 | 6 | 3 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |

| | | | |
|----------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------------|----------------|-----------------|-----------------|
| Dry skin | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Erythema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palmar-plantar erythrodysesthesia syndrome | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 3 / 24 (12.50%) | 3 / 19 (15.79%) |
| occurrences (all) | 0 | 3 | 3 |
| Rash | | | |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 2 / 19 (10.53%) |
| occurrences (all) | 0 | 0 | 2 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fragility | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hypopigmentation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitiligo | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xeroderma | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chromaturia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocyturia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------|-----------------|-----------------|----------------|
| Strangury | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 24 (8.33%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 2 | 1 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 5 / 18 (27.78%) | 1 / 24 (4.17%) | 1 / 19 (5.26%) |
| occurrences (all) | 5 | 1 | 1 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 7 / 24 (29.17%) | 1 / 19 (5.26%) |
| occurrences (all) | 2 | 8 | 1 |

| | | | |
|---------------------------------|-----------------|----------------|----------------|
| Bone pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Clubbing | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint stiffness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 1 | 1 |

| | | | |
|------------------------------------------------------------------------------------------------|----------------------|---------------------|----------------------|
| Musculoskeletal discomfort subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Musculoskeletal pain subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Musculoskeletal stiffness subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Myalgia subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 1 / 24 (4.17%) 1 | 2 / 19 (10.53%) 2 |
| Myopathy subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Neck pain subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Osteoarthritis subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 2 / 18 (11.11%) 2 | 0 / 24 (0.00%) 0 | 3 / 19 (15.79%) 3 |
| Sarcopenia subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 0 / 19 (0.00%) 0 |
| Trismus subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 1 / 24 (4.17%) 1 | 0 / 19 (0.00%) 0 |
| Infections and infestations Bacteraemia subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 24 (0.00%) 0 | 1 / 19 (5.26%) 1 |
| Bronchitis | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes virus infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised infection | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Mucosal infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal herpes | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Periodontitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |

| | | | |
|-----------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Propionibacterium infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |

| | | | |
|------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 24 (8.33%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 2 | 1 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 24 (4.17%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 6 / 18 (33.33%) | 3 / 24 (12.50%) | 6 / 19 (31.58%) |
| occurrences (all) | 6 | 4 | 6 |
| Dehydration | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 2 / 24 (8.33%) | 2 / 19 (10.53%) |
| occurrences (all) | 2 | 2 | 2 |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 3 / 24 (12.50%) | 1 / 19 (5.26%) |
| occurrences (all) | 1 | 3 | 1 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------|----------------|-----------------|-----------------|
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 24 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 2 / 24 (8.33%) | 4 / 19 (21.05%) |
| occurrences (all) | 1 | 2 | 4 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 3 / 24 (12.50%) | 2 / 19 (10.53%) |
| occurrences (all) | 1 | 3 | 2 |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 24 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| Non-serious adverse events | P2 NSCLC COMBO | P2 MELANOMA COMBO | P2 2 SCCHN COMBO |
|---------------------------------------------------------------------|-------------------|-------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 31 / 31 (100.00%) | 14 / 15 (93.33%) | 14 / 15 (93.33%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|--------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Infected neoplasm subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Neoplasm malignant subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Tumour pain subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 15 (0.00%) 0 |
| Vascular disorders | | | |
| Deep vein thrombosis subjects affected / exposed occurrences (all) | 1 / 31 (3.23%) 1 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Embolism subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Flushing subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Haematoma subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Haemorrhage subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 1 / 15 (6.67%) 1 |
| Hot flush subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 1 / 31 (3.23%) 1 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Hypotension subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 1 / 15 (6.67%) 1 | 3 / 15 (20.00%) 3 |
| Inferior vena cava stenosis | | | |

| | | | |
|------------------------------------------------------|------------------|-----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 14 / 31 (45.16%) | 5 / 15 (33.33%) | 1 / 15 (6.67%) |
| occurrences (all) | 19 | 6 | 1 |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest pain | | | |

| | | | |
|-----------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Face oedema | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 6 / 31 (19.35%) | 1 / 15 (6.67%) | 9 / 15 (60.00%) |
| occurrences (all) | 6 | 3 | 9 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 2 | 0 | 1 |
| Inflammation | | | |

| | | | |
|------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 3 / 31 (9.68%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infusion site joint swelling | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 0 / 15 (0.00%) | 3 / 15 (20.00%) |
| occurrences (all) | 3 | 0 | 4 |
| Oedema | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 3 / 15 (20.00%) | 2 / 15 (13.33%) |
| occurrences (all) | 4 | 3 | 2 |
| Pain | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |

| | | | |
|-----------------------------------------------------------------------------------------------------------------|---------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 2 / 31 (6.45%) 3 | 3 / 15 (20.00%) 3 | 0 / 15 (0.00%) 0 |
| Xerosis subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Immune system disorders Contrast media allergy subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Seasonal allergy subjects affected / exposed occurrences (all) | 1 / 31 (3.23%) 1 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Reproductive system and breast disorders Balanoposthitis subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Intermenstrual bleeding subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Pelvic pain subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Testis discomfort subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Vaginal discharge subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Vaginal haemorrhage subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |

| | | | |
|-----------------------------|------------------|-----------------|-----------------|
| Asthma | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Cough | | | |
| subjects affected / exposed | 9 / 31 (29.03%) | 3 / 15 (20.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 12 | 3 | 1 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 11 / 31 (35.48%) | 0 / 15 (0.00%) | 3 / 15 (20.00%) |
| occurrences (all) | 13 | 0 | 3 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 2 | 0 | 1 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypoxia | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|--------------------------------------|----------------|----------------|----------------|
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 1 | 0 | 1 |
| Productive cough | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 3 | 0 | 1 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 2 | 0 | 1 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 1 | 0 | 1 |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ammonia increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------|-----------------|----------------|----------------|
| Amylase decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Amylase increased | | | |
| subjects affected / exposed | 5 / 31 (16.13%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 7 | 1 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Blood alkaline phosphatase decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 6 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood creatine phosphokinase MB increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 5 / 31 (16.13%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 5 | 0 | 1 |
| Blood glucose decreased | | | |

| | | | |
|---------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 6 / 31 (19.35%) | 1 / 15 (6.67%) | 1 / 15 (6.67%) |
| occurrences (all) | 8 | 1 | 1 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blood triglycerides abnormal | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood triglycerides increased | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood urine present | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |

| | | | |
|------------------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Electrocardiogram T wave inversion | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 6 / 31 (19.35%) | 2 / 15 (13.33%) | 0 / 15 (0.00%) |
| occurrences (all) | 7 | 2 | 0 |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoglobin increased | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Heart rate decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immature granulocyte count increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lipase decreased | | | |

| | | | |
|-----------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 8 / 31 (25.81%) | 1 / 15 (6.67%) | 1 / 15 (6.67%) |
| occurrences (all) | 12 | 1 | 1 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell sedimentation rate | | | |

| | | | |
|------------------------------------------------|----------------|----------------|-----------------|
| decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cells urine positive | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tri-iodothyronine free decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Troponin I increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine leukocyte esterase positive | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 1 / 15 (6.67%) | 2 / 15 (13.33%) |
| occurrences (all) | 3 | 1 | 2 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cells urine positive | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| Contusion | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Incision site pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 2 / 15 (13.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Post procedural pruritus | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural nausea | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Procedural site reaction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stoma site pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Vascular access site rash subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Wound subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Wound dehiscence subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 1 / 15 (6.67%) 1 |
| Congenital, familial and genetic disorders Hydrocele subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Cardiac disorders Atrial fibrillation subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Cardiac failure subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Mitral valve disease subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 1 / 31 (3.23%) 1 | 0 / 15 (0.00%) 0 | 1 / 15 (6.67%) 1 |
| Sinoatrial block subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Sinus bradycardia subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Tachycardia | | | |

| | | | |
|--------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 1 / 15 (6.67%) 1 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Central nervous system mass | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 1 / 15 (6.67%) | 3 / 15 (20.00%) |
| occurrences (all) | 3 | 1 | 4 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|-------------------------------|----------------|----------------|----------------|
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 3 | 0 | 1 |
| Ophthalmic migraine | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------|-----------------|-----------------|-----------------|
| Taste disorder | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 9 / 31 (29.03%) | 3 / 15 (20.00%) | 3 / 15 (20.00%) |
| occurrences (all) | 9 | 4 | 3 |
| Eosinophilia | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Hyperleukocytosis | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytosis | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear effusion | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear inflammation | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Vestibular disorder | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Amaurosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival oedema | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Dry eye | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye disorder | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Eye oedema | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid oedema | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xerophthalmia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |

| | | | |
|-----------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 2 / 31 (6.45%) | 1 / 15 (6.67%) | 1 / 15 (6.67%) |
| occurrences (all) | 2 | 1 | 1 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 3 | 0 | 1 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal erythema | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal haemorrhage | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal pruritus | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 5 / 31 (16.13%) | 1 / 15 (6.67%) | 2 / 15 (13.33%) |
| occurrences (all) | 6 | 1 | 3 |
| Dental caries | | | |

| | | | |
|----------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 9 / 31 (29.03%) | 4 / 15 (26.67%) | 3 / 15 (20.00%) |
| occurrences (all) | 15 | 4 | 4 |
| Dry mouth | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 2 / 15 (13.33%) | 1 / 15 (6.67%) |
| occurrences (all) | 2 | 2 | 1 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 2 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal hypermotility | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Glossitis | | | |

| | | | |
|-----------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip blister | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 0 / 15 (0.00%) | 2 / 15 (13.33%) |
| occurrences (all) | 4 | 0 | 2 |
| Odynophagia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Oral lichen planus | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |

| | | | |
|------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 4 | 0 | 1 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cholestasis | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypertransaminaemia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------------|----------------|-----------------|----------------|
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Dry skin | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 2 / 15 (13.33%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 1 | 0 | 1 |
| Onychoclasia | | | |

| | | | |
|---------------------------------------------|----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 3 / 15 (20.00%) | 2 / 15 (13.33%) |
| occurrences (all) | 3 | 3 | 2 |
| Rash | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 1 / 15 (6.67%) |
| occurrences (all) | 1 | 1 | 1 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 2 / 15 (13.33%) |
| occurrences (all) | 0 | 1 | 2 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fragility | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Skin hypopigmentation | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Vitiligo | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Xeroderma | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chromaturia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematuria | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 2 | 0 | 1 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocyturia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Strangury | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 2 / 15 (13.33%) | 2 / 15 (13.33%) |
| occurrences (all) | 4 | 3 | 2 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 1 / 15 (6.67%) | 1 / 15 (6.67%) |
| occurrences (all) | 4 | 1 | 1 |
| Bone pain | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Clubbing | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint stiffness | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |

| | | | |
|-----------------------------|----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 15 (6.67%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 1 | 1 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 4 / 15 (26.67%) | 2 / 15 (13.33%) |
| occurrences (all) | 2 | 4 | 2 |
| Myopathy | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Neck pain | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Osteoarthritis | | | |

| | | | |
|---------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 3 / 31 (9.68%) 3 | 1 / 15 (6.67%) 1 | 1 / 15 (6.67%) 1 |
| Sarcopenia subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 1 / 15 (6.67%) 1 |
| Trismus subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 1 / 15 (6.67%) 1 |
| Infections and infestations | | | |
| Bacteraemia subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Bronchitis subjects affected / exposed occurrences (all) | 1 / 31 (3.23%) 1 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 2 / 31 (6.45%) 2 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Cystitis subjects affected / exposed occurrences (all) | 1 / 31 (3.23%) 1 | 1 / 15 (6.67%) 1 | 0 / 15 (0.00%) 0 |
| Ear infection subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Escherichia infection subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 1 / 15 (6.67%) 1 | 0 / 15 (0.00%) 0 |
| Fungal infection subjects affected / exposed occurrences (all) | 1 / 31 (3.23%) 1 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |
| Furuncle subjects affected / exposed occurrences (all) | 0 / 31 (0.00%) 0 | 0 / 15 (0.00%) 0 | 0 / 15 (0.00%) 0 |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Herpes virus infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal herpes | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------------|----------------|----------------|-----------------|
| Oral herpes | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral infection | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periodontitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 4 / 15 (26.67%) |
| occurrences (all) | 1 | 0 | 5 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Propionibacterium infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|------------------------------------|-----------------|----------------|-----------------|
| Sepsis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 1 | 0 | 1 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound infection | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 5 / 31 (16.13%) | 1 / 15 (6.67%) | 3 / 15 (20.00%) |
| occurrences (all) | 6 | 1 | 3 |
| Dehydration | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Folate deficiency | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 1 | 0 | 2 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 8 / 31 (25.81%) | 2 / 15 (13.33%) | 1 / 15 (6.67%) |
| occurrences (all) | 13 | 2 | 1 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 8 / 31 (25.81%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 12 | 0 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 5 / 31 (16.13%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 1 / 15 (6.67%) | 1 / 15 (6.67%) |
| occurrences (all) | 5 | 2 | 1 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 7 / 31 (22.58%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 10 | 2 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 6 / 31 (19.35%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 7 | 3 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 15 (6.67%) | 2 / 15 (13.33%) |
| occurrences (all) | 1 | 2 | 3 |
| Hypomagnesaemia | | | |

| | | | |
|-----------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 2 / 15 (13.33%) |
| occurrences (all) | 1 | 0 | 2 |
| Hyponatraemia | | | |
| subjects affected / exposed | 6 / 31 (19.35%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all) | 6 | 1 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all) | 1 | 0 | 1 |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| Non-serious adverse events | P2 RCC COMBO | P2 RCC MONO | P2 RCC CROSSOVER |
|---------------------------------------------------------------------|------------------|-------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 17 / 18 (94.44%) | 19 / 19 (100.00%) | 3 / 3 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Infected neoplasm | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Embolism | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flushing | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematoma | | | |

| | | | |
|--------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypertension | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Inferior vena cava stenosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration | | | |

| | | | |
|-----------------------------|-----------------|-----------------|---------------|
| site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 9 / 19 (47.37%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 10 | 0 |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chest pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Face oedema | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |

| | | | |
|------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 4 / 18 (22.22%) | 4 / 19 (21.05%) | 2 / 3 (66.67%) |
| occurrences (all) | 5 | 7 | 2 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperthermia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inflammation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion site joint swelling | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Non-cardiac chest pain | | | |

| | | | |
|------------------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 4 / 19 (21.05%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 4 | 1 |
| Pain | | | |
| subjects affected / exposed | 4 / 18 (22.22%) | 2 / 19 (10.53%) | 1 / 3 (33.33%) |
| occurrences (all) | 4 | 2 | 1 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 3 / 19 (15.79%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 3 | 0 |
| Xerosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Contrast media allergy | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Balanoposthitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Intermenstrual bleeding | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Testis discomfort | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vaginal discharge | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Dysphonia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 5 / 19 (26.32%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 7 | 1 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |

| | | | |
|------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 19 (5.26%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 1 | 1 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |

| | | | |
|--------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Sleep disorder subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Product issues Device dislocation subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Investigations Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 1 / 3 (33.33%) 1 |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Ammonia increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Amylase decreased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Amylase increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 1 / 19 (5.26%) 1 | 0 / 3 (0.00%) 0 |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Blood alkaline phosphatase decreased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Blood alkaline phosphatase increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 1 / 3 (33.33%) 2 |
| Blood bilirubin increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |

| | | | |
|---------------------------------------------|----------------|----------------|----------------|
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase MB increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase decreased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 19 (5.26%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 3 | 2 |
| Blood glucose decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|--------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Blood triglycerides abnormal subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Blood triglycerides increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Blood urea increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Blood uric acid increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Blood urine present subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Electrocardiogram T wave inversion subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 1 / 3 (33.33%) 2 |
| Glomerular filtration rate decreased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Glycosylated haemoglobin increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Haemoglobin increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 1 / 19 (5.26%) 1 | 0 / 3 (0.00%) 0 |
| Heart rate decreased | | | |

| | | | |
|------------------------------------------|-----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immature granulocyte count increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase decreased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 2 / 19 (10.53%) | 0 / 3 (0.00%) |
| occurrences (all) | 5 | 2 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Monocyte count increased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neutrophil count decreased | | | |

| | | | |
|---------------------------------------------|-----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell sedimentation rate decreased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Red blood cells urine positive | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tri-iodothyronine free decreased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Troponin I increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Urine leukocyte esterase positive subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Weight decreased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 2 / 3 (66.67%) 2 |
| Weight increased subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 2 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| White blood cells urine positive subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Fall subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 1 / 3 (33.33%) 1 |
| Incision site pain subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 1 / 19 (5.26%) 1 | 0 / 3 (0.00%) 0 |
| Infusion related reaction subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Post procedural pruritus subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Procedural nausea subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Procedural pain | | | |

| | | | |
|--------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural site reaction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stoma site pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site rash | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound dehiscence | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Congenital, familial and genetic disorders | | | |
| Hydrocele | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac failure | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Mitral valve disease | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinoatrial block | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus tachycardia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Central nervous system mass | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------|-----------------|-----------------|---------------|
| Dizziness | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Dizziness postural | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 2 / 19 (10.53%) | 0 / 3 (0.00%) |
| occurrences (all) | 3 | 4 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ophthalmic migraine | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------|-----------------|-----------------|----------------|
| Presyncope | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 4 / 18 (22.22%) | 2 / 19 (10.53%) | 2 / 3 (66.67%) |
| occurrences (all) | 4 | 2 | 2 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperleukocytosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Middle ear effusion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear inflammation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vestibular disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Amaurosis | | | |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid oedema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 19 (10.53%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xerophthalmia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 4 / 19 (21.05%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal erythema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| Anal pruritus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 3 / 19 (15.79%) | 0 / 3 (0.00%) |
| occurrences (all) | 3 | 6 | 0 |
| Dental caries | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 7 / 18 (38.89%) | 6 / 19 (31.58%) | 2 / 3 (66.67%) |
| occurrences (all) | 9 | 8 | 3 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------|-----------------|----------------|----------------|
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal hypermotility | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lip blister | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------|-----------------|-----------------|----------------|
| Nausea | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 2 / 19 (10.53%) | 2 / 3 (66.67%) |
| occurrences (all) | 3 | 3 | 2 |
| Odynophagia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral lichen planus | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 3 / 19 (15.79%) | 1 / 3 (33.33%) |
| occurrences (all) | 3 | 3 | 1 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |

| | | | |
|----------------------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 19 (10.53%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------------------|-----------------|-----------------|----------------|
| Dry skin | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 0 | 1 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 2 / 19 (10.53%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 2 | 1 |
| Rash | | | |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 2 / 18 (11.11%) | 2 / 19 (10.53%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fragility | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hypopigmentation | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitiligo | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xeroderma | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chromaturia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 2 | 2 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 0 | 3 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocyturia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|-------------------------------------------------|-----------------|-----------------|----------------|
| Strangury | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 4 / 19 (21.05%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 6 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 3 / 19 (15.79%) | 2 / 3 (66.67%) |
| occurrences (all) | 2 | 3 | 2 |

| | | | |
|---------------------------------|----------------|-----------------|---------------|
| Bone pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 19 (10.53%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Clubbing | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint stiffness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 3 / 19 (15.79%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------------------------------------------------------------------------|----------------------|---------------------|--------------------|
| Musculoskeletal discomfort subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Musculoskeletal pain subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Musculoskeletal stiffness subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Myalgia subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Myopathy subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Neck pain subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Osteoarthritis subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 3 / 18 (16.67%) 3 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Sarcopenia subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Trismus subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Infections and infestations Bacteraemia subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 19 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Bronchitis | | | |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes virus infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Localised infection | | | |

| | | | |
|-----------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal herpes | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periodontitis | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |

| | | | |
|-----------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Propionibacterium infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 2 / 19 (10.53%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |

| | | | |
|------------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 4 / 18 (22.22%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 4 | 2 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 5 / 19 (26.32%) | 2 / 3 (66.67%) |
| occurrences (all) | 3 | 7 | 2 |
| Dehydration | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Folate deficiency | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 0 | 1 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 0 | 1 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 1 / 19 (5.26%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 2 / 18 (11.11%) | 3 / 19 (15.79%) | 1 / 3 (33.33%) |
| occurrences (all) | 2 | 4 | 2 |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 19 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| Non-serious adverse events | P2 PROSTATE COMBO | P2 NOT ASSIGNED MONO | P2 NOT ASSIGNED COMBO |
|---------------------------------------------------------------------|--------------------------|-----------------------------|------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 13 / 14 (92.86%) | 1 / 1 (100.00%) | 1 / 2 (50.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|--------------------------------------------------------------------------|----------------------|----------------------|--------------------|
| Infected neoplasm subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Neoplasm malignant subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Tumour pain subjects affected / exposed occurrences (all) | 4 / 14 (28.57%) 4 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Vascular disorders | | | |
| Deep vein thrombosis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Embolism subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Flushing subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Haematoma subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Haemorrhage subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Hot flush subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 1 / 1 (100.00%) 1 | 0 / 2 (0.00%) 0 |
| Hypotension subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Inferior vena cava stenosis | | | |

| | | | |
|------------------------------------------------------|-----------------|---------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Venous thrombosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 2 | 0 | 2 |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chest pain | | | |

| | | | |
|-----------------------------|-----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Face oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Facial pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 4 / 14 (28.57%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inflammation | | | |

| | | | |
|------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Infusion site joint swelling | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |

| | | | |
|-----------------------------------------------------------------------------------------------------------------|---------------------|--------------------|--------------------|
| subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Xerosis subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Immune system disorders Contrast media allergy subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Seasonal allergy subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Reproductive system and breast disorders Balanoposthitis subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Intermenstrual bleeding subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Pelvic pain subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Testis discomfort subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Vaginal discharge subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Vaginal haemorrhage subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |

| | | | |
|-----------------------------|-----------------|---------------|----------------|
| Asthma | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 2 | 0 | 1 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 0 / 1 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 3 | 0 | 1 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Interstitial lung disease | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Laryngeal haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------|----------------|---------------|----------------|
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-------------------------------------------------|----------------|---------------|---------------|
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ammonia increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------|----------------|-----------------|---------------|
| Amylase decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Amylase increased | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase MB increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Blood glucose decreased | | | |

| | | | |
|---------------------------------------------|-----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood triglycerides abnormal | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood triglycerides increased | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Blood uric acid increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urine present | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |

| | | | |
|------------------------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Electrocardiogram T wave inversion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glomerular filtration rate decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Glycosylated haemoglobin increased | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haemoglobin increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immature granulocyte count increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| International normalised ratio increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase decreased | | | |

| | | | |
|-----------------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Liver function test increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lymphocyte percentage decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Monocyte count increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neutrophil percentage increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Red blood cell sedimentation rate | | | |

| | | | |
|------------------------------------------------|----------------|-----------------|---------------|
| decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cells urine positive | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tri-iodothyronine free decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Troponin I increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine leukocyte esterase positive | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| White blood cells urine positive | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|-----------------------------|----------------|---------------|---------------|
| Contusion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Incision site pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Post procedural pruritus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural nausea | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural site reaction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stoma site pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access site pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------------------------------------------------------------------|---------------------|--------------------|--------------------|
| Vascular access site rash subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Wound subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Wound dehiscence subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Congenital, familial and genetic disorders Hydrocele subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Cardiac disorders Atrial fibrillation subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Cardiac failure subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Mitral valve disease subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Sinoatrial block subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Sinus bradycardia subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Tachycardia | | | |

| | | | |
|--------------------------------------------------|---------------------|--------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Aphasia | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Burning sensation | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Central nervous system mass | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Dizziness | | | |
| subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Dizziness postural | | | |
| subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 2 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Dysarthria | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Dysgeusia | | | |
| subjects affected / exposed occurrences (all) | 1 / 14 (7.14%) 1 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Headache | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed occurrences (all) | 0 / 14 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 |

| | | | |
|-------------------------------|----------------|-----------------|---------------|
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ophthalmic migraine | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------------|-----------------|-----------------|---------------|
| Taste disorder | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperleukocytosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Middle ear effusion | | | |

| | | | |
|-----------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Middle ear inflammation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vestibular disorder | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye disorders | | | |
| Amaurosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctival oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorder | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|---------------|---------------|
| Eye oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eyelid oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xerophthalmia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Abdominal pain | | | |

| | | | |
|-----------------------------|-----------------|-----------------|---------------|
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal erythema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal haemorrhage | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Anal pruritus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 4 / 14 (28.57%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 6 | 1 | 0 |
| Dental caries | | | |

| | | | |
|----------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Epigastric discomfort | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal hypermotility | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glossitis | | | |

| | | | |
|-----------------------------|-----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip blister | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Odynophagia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral lichen planus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |

| | | | |
|------------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------------|----------------|---------------|---------------|
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lichenoid keratosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |

| | | | |
|---------------------------------------------|-----------------|---------------|----------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain of skin | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 1 / 2 (50.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fissures | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin fragility | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin hyperpigmentation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| Skin hypopigmentation | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitiligo | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Xeroderma | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chromaturia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematuria | | | |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Leukocyturia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nocturia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Strangury | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------|-----------------|-----------------|---------------|
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 3 / 14 (21.43%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Clubbing | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flank pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Joint stiffness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |

| | | | |
|-----------------------------|-----------------|---------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Myopathy | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |

| | | | |
|-----------------------------|----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Sarcopenia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Trismus | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Escherichia infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|----------------|---------------|---------------|
| Herpes virus infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail infection | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal herpes | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------------|----------------|---------------|---------------|
| Oral herpes | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Periodontitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Propionibacterium infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purulent discharge | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal abscess | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------------|----------------|---------------|---------------|
| Sepsis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dehydration | | | |

| | | | |
|-----------------------------|-----------------|-----------------|---------------|
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 1 / 1 (100.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 2 / 14 (14.29%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |

| | | | |
|-----------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 1 / 14 (7.14%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency | | | |
| subjects affected / exposed | 0 / 14 (0.00%) | 0 / 1 (0.00%) | 0 / 2 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | P2 ALL COMBO | ALL COMBO (P1A+P1B+P2) | |
|---------------------------------------------------------------------|--------------------|---------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 110 / 117 (94.02%) | 181 / 193 (93.78%) | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Infected neoplasm | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Tumour pain | | | |
| subjects affected / exposed | 6 / 117 (5.13%) | 9 / 193 (4.66%) | |
| occurrences (all) | 6 | 9 | |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Embolism | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Flushing | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Haematoma | | | |

| | | | |
|--------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Haemorrhage | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Hot flush | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) | |
| occurrences (all) | 3 | 3 | |
| Hypertension | | | |
| subjects affected / exposed | 5 / 117 (4.27%) | 7 / 193 (3.63%) | |
| occurrences (all) | 6 | 8 | |
| Hypotension | | | |
| subjects affected / exposed | 7 / 117 (5.98%) | 8 / 193 (4.15%) | |
| occurrences (all) | 7 | 8 | |
| Inferior vena cava stenosis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) | |
| occurrences (all) | 2 | 2 | |
| Thrombosis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Vasculitis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Vena cava thrombosis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Venous thrombosis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| General disorders and administration | | | |

| | | | |
|-----------------------------|-------------------|-------------------|--|
| site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 30 / 117 (25.64%) | 40 / 193 (20.73%) | |
| occurrences (all) | 38 | 49 | |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Catheter site pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Chest pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Chills | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Device related thrombosis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Discomfort | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Early satiety | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) | |
| occurrences (all) | 0 | 2 | |
| Face oedema | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 4 / 193 (2.07%) | |
| occurrences (all) | 2 | 4 | |
| Facial pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Fatigue | | | |

| | | |
|------------------------------|-------------------|-------------------|
| subjects affected / exposed | 32 / 117 (27.35%) | 56 / 193 (29.02%) |
| occurrences (all) | 35 | 60 |
| Feeling cold | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Gait disturbance | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Generalised oedema | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Hyperthermia | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 4 / 193 (2.07%) |
| occurrences (all) | 3 | 5 |
| Inflammation | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 4 / 193 (2.07%) |
| occurrences (all) | 3 | 4 |
| Influenza like illness | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 7 / 193 (3.63%) |
| occurrences (all) | 3 | 9 |
| Infusion site joint swelling | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Injection site reaction | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Localised oedema | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) |
| occurrences (all) | 2 | 3 |
| Malaise | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) |
| occurrences (all) | 0 | 3 |
| Mucosal inflammation | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 6 / 193 (3.11%) |
| occurrences (all) | 3 | 6 |
| Non-cardiac chest pain | | |

| | | | |
|------------------------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 8 / 117 (6.84%) | 11 / 193 (5.70%) | |
| occurrences (all) | 9 | 12 | |
| Oedema | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Oedema peripheral | | | |
| subjects affected / exposed | 19 / 117 (16.24%) | 43 / 193 (22.28%) | |
| occurrences (all) | 19 | 44 | |
| Pain | | | |
| subjects affected / exposed | 10 / 117 (8.55%) | 12 / 193 (6.22%) | |
| occurrences (all) | 11 | 13 | |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Pyrexia | | | |
| subjects affected / exposed | 12 / 117 (10.26%) | 24 / 193 (12.44%) | |
| occurrences (all) | 13 | 27 | |
| Xerosis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Immune system disorders | | | |
| Contrast media allergy | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Seasonal allergy | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Reproductive system and breast disorders | | | |
| Balanoposthitis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Intermenstrual bleeding | | | |

| | | | |
|-------------------------------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Testis discomfort | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Vaginal discharge | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Cough | | | |
| subjects affected / exposed | 22 / 117 (18.80%) | 39 / 193 (20.21%) | |
| occurrences (all) | 26 | 45 | |
| Dysphonia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 3 / 193 (1.55%) | |
| occurrences (all) | 1 | 3 | |
| Dyspnoea | | | |
| subjects affected / exposed | 26 / 117 (22.22%) | 42 / 193 (21.76%) | |
| occurrences (all) | 28 | 44 | |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) | |
| occurrences (all) | 2 | 3 | |
| Haemoptysis | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) | |
| occurrences (all) | 3 | 3 | |
| Hiccups | | | |

| | | |
|------------------------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Hypoxia | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Interstitial lung disease | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Laryngeal haemorrhage | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Nasal congestion | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 7 / 193 (3.63%) |
| occurrences (all) | 1 | 7 |
| Oropharyngeal pain | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 3 / 193 (1.55%) |
| occurrences (all) | 1 | 3 |
| Pleural effusion | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 5 / 193 (2.59%) |
| occurrences (all) | 3 | 5 |
| Pleuritic pain | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Pneumonitis | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) |
| occurrences (all) | 2 | 3 |
| Pneumothorax | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 4 / 193 (2.07%) |
| occurrences (all) | 4 | 4 |
| Productive cough | | |
| subjects affected / exposed | 5 / 117 (4.27%) | 7 / 193 (3.63%) |
| occurrences (all) | 5 | 7 |
| Pulmonary embolism | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Respiratory tract congestion | | |

| | | | |
|--------------------------------------|-----------------|------------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Rhinitis allergic | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) | |
| occurrences (all) | 0 | 2 | |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 3 / 193 (1.55%) | |
| occurrences (all) | 1 | 3 | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 6 / 117 (5.13%) | 12 / 193 (6.22%) | |
| occurrences (all) | 6 | 12 | |
| Confusional state | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Depression | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 3 / 193 (1.55%) | |
| occurrences (all) | 1 | 3 | |
| Hallucination | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Insomnia | | | |
| subjects affected / exposed | 5 / 117 (4.27%) | 13 / 193 (6.74%) | |
| occurrences (all) | 5 | 13 | |
| Restlessness | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------|--|
| Sleep disorder subjects affected / exposed occurrences (all) | 2 / 117 (1.71%) 2 | 2 / 193 (1.04%) 2 | |
| Product issues Device dislocation subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Investigations Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all) | 2 / 117 (1.71%) 2 | 3 / 193 (1.55%) 3 | |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 3 / 117 (2.56%) 4 | 8 / 193 (4.15%) 9 | |
| Ammonia increased subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Amylase decreased subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Amylase increased subjects affected / exposed occurrences (all) | 7 / 117 (5.98%) 9 | 11 / 193 (5.70%) 15 | |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 9 / 117 (7.69%) 10 | 12 / 193 (6.22%) 13 | |
| Blood alkaline phosphatase decreased subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Blood alkaline phosphatase increased subjects affected / exposed occurrences (all) | 8 / 117 (6.84%) 11 | 10 / 193 (5.18%) 13 | |
| Blood bilirubin increased subjects affected / exposed occurrences (all) | 4 / 117 (3.42%) 5 | 5 / 193 (2.59%) 7 | |

| | | |
|---------------------------------------------|-----------------|------------------|
| Blood cholesterol increased | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Blood creatine phosphokinase MB increased | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 2 |
| Blood creatine phosphokinase decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Blood creatine phosphokinase increased | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 6 / 193 (3.11%) |
| occurrences (all) | 3 | 7 |
| Blood creatinine increased | | |
| subjects affected / exposed | 8 / 117 (6.84%) | 13 / 193 (6.74%) |
| occurrences (all) | 10 | 17 |
| Blood glucose decreased | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Blood iron decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Blood lactate dehydrogenase increased | | |
| subjects affected / exposed | 8 / 117 (6.84%) | 9 / 193 (4.66%) |
| occurrences (all) | 10 | 11 |
| Blood pressure increased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Blood thyroid stimulating hormone decreased | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) |
| occurrences (all) | 4 | 4 |
| Blood thyroid stimulating hormone increased | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 4 / 193 (2.07%) |
| occurrences (all) | 3 | 5 |

| | | | |
|--------------------------------------------------------------------------------------------|------------------------|------------------------|--|
| Blood triglycerides abnormal subjects affected / exposed occurrences (all) | 2 / 117 (1.71%) 2 | 2 / 193 (1.04%) 2 | |
| Blood triglycerides increased subjects affected / exposed occurrences (all) | 4 / 117 (3.42%) 4 | 4 / 193 (2.07%) 4 | |
| Blood urea increased subjects affected / exposed occurrences (all) | 4 / 117 (3.42%) 4 | 4 / 193 (2.07%) 4 | |
| Blood uric acid increased subjects affected / exposed occurrences (all) | 2 / 117 (1.71%) 2 | 2 / 193 (1.04%) 2 | |
| Blood urine present subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| C-reactive protein increased subjects affected / exposed occurrences (all) | 3 / 117 (2.56%) 3 | 3 / 193 (1.55%) 3 | |
| Electrocardiogram T wave inversion subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) | 10 / 117 (8.55%) 12 | 12 / 193 (6.22%) 14 | |
| Glomerular filtration rate decreased subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Glycosylated haemoglobin increased subjects affected / exposed occurrences (all) | 2 / 117 (1.71%) 2 | 2 / 193 (1.04%) 2 | |
| Haemoglobin increased subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Heart rate decreased | | | |

| | | |
|------------------------------------------|-------------------|------------------|
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 7 | 7 |
| Heart rate increased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 2 | 2 |
| Hepatic enzyme increased | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Immature granulocyte count increased | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| International normalised ratio increased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |
| Lipase decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 2 | 2 |
| Lipase increased | | |
| subjects affected / exposed | 14 / 117 (11.97%) | 19 / 193 (9.84%) |
| occurrences (all) | 20 | 31 |
| Liver function test increased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 2 | 2 |
| Lymphocyte count decreased | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) |
| occurrences (all) | 5 | 5 |
| Lymphocyte percentage decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Monocyte count increased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Neutrophil count decreased | | |

| | | |
|---------------------------------------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Neutrophil count increased | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) |
| occurrences (all) | 3 | 4 |
| Neutrophil percentage increased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Platelet count decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Protein total decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 2 | 2 |
| Red blood cell count decreased | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Red blood cell sedimentation rate decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Red blood cells urine positive | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| SARS-CoV-2 test positive | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Transaminases increased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Tri-iodothyronine free decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Troponin I increased | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |

| | | | |
|---------------------------------------------------------------------------------------|----------------------|------------------------|--|
| Urine leukocyte esterase positive subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Weight decreased subjects affected / exposed occurrences (all) | 9 / 117 (7.69%) 9 | 16 / 193 (8.29%) 16 | |
| Weight increased subjects affected / exposed occurrences (all) | 0 / 117 (0.00%) 0 | 2 / 193 (1.04%) 3 | |
| White blood cell count increased subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 2 | 2 / 193 (1.04%) 3 | |
| White blood cells urine positive subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 117 (0.00%) 0 | 2 / 193 (1.04%) 4 | |
| Fall subjects affected / exposed occurrences (all) | 3 / 117 (2.56%) 3 | 3 / 193 (1.55%) 3 | |
| Incision site pain subjects affected / exposed occurrences (all) | 0 / 117 (0.00%) 0 | 0 / 193 (0.00%) 0 | |
| Infusion related reaction subjects affected / exposed occurrences (all) | 6 / 117 (5.13%) 6 | 8 / 193 (4.15%) 8 | |
| Post procedural pruritus subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Procedural nausea subjects affected / exposed occurrences (all) | 0 / 117 (0.00%) 0 | 1 / 193 (0.52%) 1 | |
| Procedural pain | | | |

| | | | |
|--------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) | |
| occurrences (all) | 2 | 3 | |
| Procedural site reaction | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Stoma site pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Vascular access site pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Vascular access site rash | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Wound | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Wound dehiscence | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Congenital, familial and genetic disorders | | | |
| Hydrocele | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Cardiac failure | | | |

| | | | |
|-----------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) | |
| occurrences (all) | 2 | 2 | |
| Mitral valve disease | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Palpitations | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 4 / 193 (2.07%) | |
| occurrences (all) | 3 | 4 | |
| Sinoatrial block | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Sinus tachycardia | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Tachycardia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Aphasia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Burning sensation | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) | |
| occurrences (all) | 0 | 2 | |
| Central nervous system mass | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |

| | | |
|-------------------------------|------------------|------------------|
| Dizziness | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 6 / 193 (3.11%) |
| occurrences (all) | 4 | 7 |
| Dizziness postural | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 2 | 2 |
| Dysarthria | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Dysgeusia | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) |
| occurrences (all) | 2 | 3 |
| Headache | | |
| subjects affected / exposed | 10 / 117 (8.55%) | 16 / 193 (8.29%) |
| occurrences (all) | 11 | 18 |
| Hypoaesthesia | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) |
| occurrences (all) | 2 | 3 |
| Loss of consciousness | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Memory impairment | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Neuropathy peripheral | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 8 / 193 (4.15%) |
| occurrences (all) | 4 | 8 |
| Ophthalmic migraine | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Paraesthesia | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 4 / 193 (2.07%) |
| occurrences (all) | 3 | 4 |
| Peripheral sensory neuropathy | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |

| | | | |
|--------------------------------------|-------------------|-------------------|--|
| Presyncope | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Sciatica | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Seizure | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Somnolence | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 4 / 193 (2.07%) | |
| occurrences (all) | 3 | 4 | |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Taste disorder | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Tremor | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 25 / 117 (21.37%) | 38 / 193 (19.69%) | |
| occurrences (all) | 26 | 42 | |
| Eosinophilia | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) | |
| occurrences (all) | 4 | 4 | |
| Hyperleukocytosis | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) | |
| occurrences (all) | 2 | 2 | |
| Iron deficiency anaemia | | | |

| | | | |
|-----------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Leukocytosis | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) | |
| occurrences (all) | 2 | 2 | |
| Lymphopenia | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) | |
| occurrences (all) | 2 | 2 | |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Thrombocytosis | | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 4 / 193 (2.07%) | |
| occurrences (all) | 5 | 5 | |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Middle ear effusion | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Middle ear inflammation | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Vertigo | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) | |
| occurrences (all) | 3 | 3 | |
| Vestibular disorder | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Eye disorders | | | |
| Amaurosis | | | |

| | | |
|-----------------------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Conjunctival haemorrhage | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Conjunctival oedema | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Diplopia | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Dry eye | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 4 / 193 (2.07%) |
| occurrences (all) | 1 | 4 |
| Eye disorder | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Eye irritation | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 3 |
| Eye oedema | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Eye pruritus | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 3 / 193 (1.55%) |
| occurrences (all) | 0 | 3 |
| Eyelid oedema | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |
| Lacrimation increased | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) |
| occurrences (all) | 0 | 2 |
| Ocular hyperaemia | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Periorbital oedema | | |

| | | | |
|-----------------------------|------------------|-------------------|--|
| subjects affected / exposed | 0 / 117 (0.00%) | 3 / 193 (1.55%) | |
| occurrences (all) | 0 | 4 | |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 3 / 193 (1.55%) | |
| occurrences (all) | 0 | 3 | |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Xerophthalmia | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Abdominal distension | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 7 / 193 (3.63%) | |
| occurrences (all) | 2 | 7 | |
| Abdominal pain | | | |
| subjects affected / exposed | 11 / 117 (9.40%) | 20 / 193 (10.36%) | |
| occurrences (all) | 12 | 27 | |
| Abdominal pain lower | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 7 / 117 (5.98%) | 11 / 193 (5.70%) | |
| occurrences (all) | 8 | 12 | |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Anal erythema | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Anal haemorrhage | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |

| | | |
|-----------------------------|-------------------|-------------------|
| Anal pruritus | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Aphthous ulcer | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Ascites | | |
| subjects affected / exposed | 7 / 117 (5.98%) | 10 / 193 (5.18%) |
| occurrences (all) | 7 | 10 |
| Cheilitis | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |
| Colitis | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Constipation | | |
| subjects affected / exposed | 19 / 117 (16.24%) | 37 / 193 (19.17%) |
| occurrences (all) | 23 | 42 |
| Dental caries | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Diarrhoea | | |
| subjects affected / exposed | 27 / 117 (23.08%) | 45 / 193 (23.32%) |
| occurrences (all) | 39 | 62 |
| Dry mouth | | |
| subjects affected / exposed | 6 / 117 (5.13%) | 15 / 193 (7.77%) |
| occurrences (all) | 6 | 16 |
| Dyspepsia | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 4 / 193 (2.07%) |
| occurrences (all) | 2 | 5 |
| Dysphagia | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) |
| occurrences (all) | 3 | 3 |
| Epigastric discomfort | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |

| | | |
|----------------------------------|-----------------|-----------------|
| Faeces discoloured | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Flatulence | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 4 / 193 (2.07%) |
| occurrences (all) | 1 | 4 |
| Gastrointestinal disorder | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) |
| occurrences (all) | 0 | 2 |
| Gastrointestinal hypermotility | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |
| Gastrooesophageal reflux disease | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 7 / 193 (3.63%) |
| occurrences (all) | 4 | 7 |
| Gingival pain | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |
| Glossitis | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Haemorrhoidal haemorrhage | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Haemorrhoids | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 4 / 193 (2.07%) |
| occurrences (all) | 2 | 4 |
| Lip blister | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Melaena | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Mouth ulceration | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |

| | | | |
|------------------------------|-------------------|-------------------|--|
| Nausea | | | |
| subjects affected / exposed | 17 / 117 (14.53%) | 34 / 193 (17.62%) | |
| occurrences (all) | 18 | 40 | |
| Odynophagia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 3 | |
| Oral disorder | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Oral lichen planus | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) | |
| occurrences (all) | 2 | 3 | |
| Paraesthesia oral | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Stomatitis | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) | |
| occurrences (all) | 2 | 3 | |
| Toothache | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Vomiting | | | |
| subjects affected / exposed | 11 / 117 (9.40%) | 26 / 193 (13.47%) | |
| occurrences (all) | 12 | 32 | |
| Hepatobiliary disorders | | | |
| Bile duct stenosis | | | |

| | | | |
|----------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Cholestasis | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) | |
| occurrences (all) | 2 | 3 | |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Immune-mediated hepatitis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 3 | |
| Jaundice | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Blister | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Decubitus ulcer | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 3 / 193 (1.55%) | |
| occurrences (all) | 1 | 4 | |
| Dermatitis contact | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |

| | | |
|--------------------------------------------|-------------------|-------------------|
| Dry skin | | |
| subjects affected / exposed | 6 / 117 (5.13%) | 10 / 193 (5.18%) |
| occurrences (all) | 6 | 10 |
| Ecchymosis | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Erythema | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 3 / 193 (1.55%) |
| occurrences (all) | 0 | 3 |
| Hyperhidrosis | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Lichenoid keratosis | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Night sweats | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) |
| occurrences (all) | 2 | 3 |
| Onychoclasia | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Pain of skin | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Palmar-plantar erythrodysesthesia syndrome | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Photosensitivity reaction | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Pruritus | | |
| subjects affected / exposed | 17 / 117 (14.53%) | 25 / 193 (12.95%) |
| occurrences (all) | 17 | 25 |
| Rash | | |

| | | |
|-----------------------------|-----------------|------------------|
| subjects affected / exposed | 8 / 117 (6.84%) | 13 / 193 (6.74%) |
| occurrences (all) | 8 | 15 |
| Rash macular | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Rash maculo-papular | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 7 / 193 (3.63%) |
| occurrences (all) | 4 | 7 |
| Rash pruritic | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Skin fissures | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Skin fragility | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Skin hyperpigmentation | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Skin hypopigmentation | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Skin induration | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Skin lesion | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Skin ulcer | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Urticaria | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 3 / 193 (1.55%) |
| occurrences (all) | 1 | 3 |
| Vitiligo | | |

| | | | |
|-----------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Xeroderma | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Chromaturia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Chronic kidney disease | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 2 | 2 | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) | |
| occurrences (all) | 0 | 2 | |
| Haematuria | | | |
| subjects affected / exposed | 5 / 117 (4.27%) | 5 / 193 (2.59%) | |
| occurrences (all) | 8 | 8 | |
| Hydronephrosis | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Leukocyturia | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Nocturia | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Proteinuria | | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) | |
| occurrences (all) | 3 | 4 | |

| | | | |
|-------------------------------------------------|-------------------|-------------------|--|
| Strangury | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Urinary incontinence | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Urinary retention | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Hyperthyroidism | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 4 / 193 (2.07%) | |
| occurrences (all) | 3 | 4 | |
| Hypothyroidism | | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 11 / 193 (5.70%) | |
| occurrences (all) | 5 | 12 | |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 14 / 117 (11.97%) | 22 / 193 (11.40%) | |
| occurrences (all) | 16 | 26 | |
| Arthritis | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 3 / 193 (1.55%) | |
| occurrences (all) | 0 | 3 | |
| Back pain | | | |
| subjects affected / exposed | 12 / 117 (10.26%) | 27 / 193 (13.99%) | |
| occurrences (all) | 13 | 29 | |

| | | |
|---------------------------------|-----------------|-----------------|
| Bone pain | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 4 / 193 (2.07%) |
| occurrences (all) | 2 | 4 |
| Clubbing | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Coccydynia | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Flank pain | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 4 / 193 (2.07%) |
| occurrences (all) | 1 | 5 |
| Joint range of motion decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |
| Joint stiffness | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Joint swelling | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Limb discomfort | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Mobility decreased | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Muscle spasms | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 9 / 193 (4.66%) |
| occurrences (all) | 5 | 10 |
| Muscular weakness | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 7 / 193 (3.63%) |
| occurrences (all) | 4 | 7 |
| Musculoskeletal chest pain | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 8 / 193 (4.15%) |
| occurrences (all) | 4 | 8 |

| | | | |
|------------------------------------------------------------------------------------------------|-------------------------|------------------------|--|
| Musculoskeletal discomfort subjects affected / exposed occurrences (all) | 0 / 117 (0.00%) 0 | 0 / 193 (0.00%) 0 | |
| Musculoskeletal pain subjects affected / exposed occurrences (all) | 4 / 117 (3.42%) 4 | 5 / 193 (2.59%) 5 | |
| Musculoskeletal stiffness subjects affected / exposed occurrences (all) | 0 / 117 (0.00%) 0 | 1 / 193 (0.52%) 1 | |
| Myalgia subjects affected / exposed occurrences (all) | 13 / 117 (11.11%) 13 | 17 / 193 (8.81%) 17 | |
| Myopathy subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Neck pain subjects affected / exposed occurrences (all) | 3 / 117 (2.56%) 3 | 5 / 193 (2.59%) 6 | |
| Osteoarthritis subjects affected / exposed occurrences (all) | 0 / 117 (0.00%) 0 | 1 / 193 (0.52%) 1 | |
| Pain in extremity subjects affected / exposed occurrences (all) | 11 / 117 (9.40%) 11 | 15 / 193 (7.77%) 15 | |
| Sarcopenia subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Trismus subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 2 / 193 (1.04%) 2 | |
| Infections and infestations Bacteraemia subjects affected / exposed occurrences (all) | 1 / 117 (0.85%) 1 | 1 / 193 (0.52%) 1 | |
| Bronchitis | | | |

| | | |
|-----------------------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 117 (1.71%) | 4 / 193 (2.07%) |
| occurrences (all) | 2 | 4 |
| Conjunctivitis | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Cystitis | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) |
| occurrences (all) | 3 | 3 |
| Ear infection | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Escherichia infection | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Fungal infection | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Furuncle | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Herpes virus infection | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Herpes zoster | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Infection | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Influenza | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Laryngitis | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Localised infection | | |

| | | |
|-----------------------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Mucosal infection | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Nail infection | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Nasal herpes | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Nasopharyngitis | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 4 / 193 (2.07%) |
| occurrences (all) | 1 | 4 |
| Onychomycosis | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Oral candidiasis | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Oral herpes | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Oral infection | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 2 / 193 (1.04%) |
| occurrences (all) | 2 | 2 |
| Otitis externa | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 2 / 193 (1.04%) |
| occurrences (all) | 0 | 2 |
| Periodontitis | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Pharyngitis | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) |
| occurrences (all) | 0 | 1 |
| Pneumonia | | |

| | | |
|-----------------------------------|-----------------|-----------------|
| subjects affected / exposed | 5 / 117 (4.27%) | 8 / 193 (4.15%) |
| occurrences (all) | 6 | 9 |
| Pneumonia aspiration | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Propionibacterium infection | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Purulent discharge | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Renal abscess | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Respiratory tract infection viral | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Rhinitis | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 4 / 193 (2.07%) |
| occurrences (all) | 2 | 4 |
| Sepsis | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Sinusitis | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 0 / 193 (0.00%) |
| occurrences (all) | 0 | 0 |
| Skin infection | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |
| Tooth abscess | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) |
| occurrences (all) | 1 | 2 |
| Tooth infection | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) |
| occurrences (all) | 1 | 1 |
| Upper respiratory tract infection | | |

| | | | |
|------------------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 3 / 117 (2.56%) | 8 / 193 (4.15%) | |
| occurrences (all) | 3 | 8 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 7 / 117 (5.98%) | 12 / 193 (6.22%) | |
| occurrences (all) | 7 | 12 | |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Viral infection | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 2 / 193 (1.04%) | |
| occurrences (all) | 1 | 2 | |
| Wound infection | | | |
| subjects affected / exposed | 1 / 117 (0.85%) | 1 / 193 (0.52%) | |
| occurrences (all) | 1 | 1 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 21 / 117 (17.95%) | 35 / 193 (18.13%) | |
| occurrences (all) | 22 | 37 | |
| Dehydration | | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 8 / 193 (4.15%) | |
| occurrences (all) | 4 | 8 | |
| Folate deficiency | | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 3 / 193 (1.55%) | |
| occurrences (all) | 3 | 3 | |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 117 (0.00%) | 1 / 193 (0.52%) | |
| occurrences (all) | 0 | 1 | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 5 / 117 (4.27%) | 10 / 193 (5.18%) | |
| occurrences (all) | 7 | 12 | |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 11 / 117 (9.40%) | 11 / 193 (5.70%) | |
| occurrences (all) | 16 | 16 | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 8 / 117 (6.84%) | 9 / 193 (4.66%) | |
| occurrences (all) | 12 | 16 | |

| | | |
|-----------------------------|-------------------|------------------|
| Hyperkalaemia | | |
| subjects affected / exposed | 5 / 117 (4.27%) | 7 / 193 (3.63%) |
| occurrences (all) | 5 | 7 |
| Hypertriglyceridaemia | | |
| subjects affected / exposed | 5 / 117 (4.27%) | 5 / 193 (2.59%) |
| occurrences (all) | 8 | 8 |
| Hyperuricaemia | | |
| subjects affected / exposed | 8 / 117 (6.84%) | 8 / 193 (4.15%) |
| occurrences (all) | 12 | 12 |
| Hypoalbuminaemia | | |
| subjects affected / exposed | 12 / 117 (10.26%) | 16 / 193 (8.29%) |
| occurrences (all) | 15 | 20 |
| Hypocalcaemia | | |
| subjects affected / exposed | 3 / 117 (2.56%) | 5 / 193 (2.59%) |
| occurrences (all) | 3 | 5 |
| Hypokalaemia | | |
| subjects affected / exposed | 4 / 117 (3.42%) | 5 / 193 (2.59%) |
| occurrences (all) | 6 | 7 |
| Hypomagnesaemia | | |
| subjects affected / exposed | 6 / 117 (5.13%) | 12 / 193 (6.22%) |
| occurrences (all) | 6 | 12 |
| Hyponatraemia | | |
| subjects affected / exposed | 12 / 117 (10.26%) | 16 / 193 (8.29%) |
| occurrences (all) | 12 | 16 |
| Hypophosphataemia | | |
| subjects affected / exposed | 7 / 117 (5.98%) | 12 / 193 (6.22%) |
| occurrences (all) | 8 | 13 |
| Iron deficiency | | |
| subjects affected / exposed | 2 / 117 (1.71%) | 3 / 193 (1.55%) |
| occurrences (all) | 2 | 3 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12 April 2016 | <ol style="list-style-type: none"> 1) Added rationale for sentinel subject approach 2) Added additional rationales for 6 weeks DLT in dose escalation, and for initiation of PD substudy 3) Revised treatment arms and sample sizes for PD substudy 4) Revised vital sign measurements during infusions 5) Procedure clarifications and typographic changes |
| 31 May 2016 | <ol style="list-style-type: none"> 1) Revised Target Population in Inclusion Criteria in Section 3.3.1 2) Revised Dose-limiting Toxicities in Section 4.5.1 |
| 06 June 2016 | <ol style="list-style-type: none"> 1) Clarified rationales for 2 week lead-in and for dose selection in Sections 1.1.3 and 1.1.5.1, respectively 2) Added a 9 day waiting period for doses over 400 mg, and revised waiting periods for each dose level Sections 1.1.7 and 3.1.1, respectively 3) Clarified definition of treatment arm and number of arms in Part 1B in Sections 3.1.2 and 8.3.1 4) Clarified requirement for dose delay in Part 1A in Section 4.5.4 5) Added language to allow for collection and central review of imaging assessments in Section 5.4 6) Editorial changes throughout the protocol |
| 26 October 2016 | <ol style="list-style-type: none"> 1) Included updates made in nivolumab IBv15 in Sections 1.4.4, 3.3.1, and Appendix 1, respectively 2) Added text describing vascular effects in mouse models in literature, and added dose delay in Section 1.5 3) Prohibited use of dipyridamole 2 weeks prior to the first dose and during treatment in Section 3.4.1 4) Removed windows for dosing visits and further clarified minimum treatment interval between 2 doses in Sections 5.1 and 4.5, respectively 5) Revised and clarified requirements for minimum dosing interval, dose delay due to toxicity, medical events or non-medical events, hepatic nonhematologic DLT, and removed tumor assessment procedure when study drugs are permanently discontinued in Section 4.5 6) In Section 5.1, revised Vital Signs requirements during initial treatment and re-treatment in Parts 1B and 2, removed pregnancy test on Days 8 and 22 during retreatment in Q1W, and added windows for tumor assessment during follow-ups 7) Clarified DILI criteria for subjects with abnormal ALT or AST at baseline in Section 6.6 8) Added 1 new reference in Section 12 9) Editorial changes throughout the protocol |
| 16 March 2017 | Incorporates Administrative Letters 01 and 02, and Amendments 01, 02, 03, 05 and 07 |
| 16 March 2017 | <ol style="list-style-type: none"> 1) Included additional exclusion criteria for cardiovascular and cerebrovascular disease in Section 3.1.2 2) Added a new Section 3.4.4 to ensure appropriate assessment and management of cardiovascular risk factors 3) Updated dose delay criteria for subjects with any investigation or symptoms suggestive of possible thrombotic or ischemic events during treatment in Section 4.5.4.1 4) Updated guidelines to permanently discontinue BMS-986179 in subjects with any myocardial infarction or thrombotic/ischemic cerebrovascular event during treatment in Section 4.5.6 |

| | |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20 October 2017 | <ol style="list-style-type: none"> 1) Changed the tumor types in Part 2, Cohort Expansion to add nonsmall cell lung cancer (NSCLC), renal cell cancer (RCC), castrateresistant prostate carcinoma, squamous cell carcinoma of the head and neck, and melanoma, and to delete ovarian cancer, colorectal cancer, and gastric cancer 2) Allowed for monotherapy in Part 2 with BMS-986179 in NSCLC and RCC, with the option for subjects to receive combination therapy with BMS-986179 and nivolumab at disease progression 3) Changed the treatment duration to 2 years, changed follow-up to 3 years after initial dose, and added a Q4W regimen for combination therapy with BMS-986179 and nivolumab 4) Added plasma sample collection for ctDNA extraction for assessment of tumor mutational burden in Section 5.7.1.6 5) Added laboratory parameters HbA1c, cardiovascular lipid profile, and PSA to list of assessments in Section 5.3.2 6) Added clinical observations and supporting data throughout Section 1.1 7) Added a replacement criterion to allow subjects without both pre- and on-treatment tumor biopsies, or whose biopsies are uninformative, to be replaced 8) Increased the number of pre-treatment core biopsy specimens from 2 to either 4 (for NSCLC, melanoma, and SCCHN) or 3 (for all other tumor types) 9) Changed the name of the Study Director/Medical Monitor 10) Editorial changes throughout the protocol |
| 28 February 2018 | <ol style="list-style-type: none"> 1) Subcutaneous dosing objective has been added to Part 1B of this study to assess a potentially important alternative approach to dosing. 2) Added background for rHuPH20, which enables SC administration of BMS-986179. 3) Sections added or modified based on addition of objective to assess tumors using iRECIST criteria by BICR. 4) New PK tables were added to support assessment for PK in subjects receiving subcutaneous dose. |
| 30 November 2018 | <ol style="list-style-type: none"> 1) Selection strategy has been modified based on new data on adenosineaxis that is more specific to the pathway being targeted by BMS-986179. 2) Data from completed toxicokinetics study has been added to provide additional safety information. 3) Part 2 expansion cohorts in the tumor-specific indications with high unmet medical need are open. Cardiovascular disease is prevalent in these indications. 4) Cardiovascular exclusion criteria has been modified. Under this modification, some asymptomatic patients with history of cardiovascular disease may be permitted to enroll after mandatory evaluation by specialist that includes functional ischemic test. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported